

**CURRICULUM VITAE**  
**MINESH P. MEHTA, M.D.**

Comment:

**ADDRESS:** University of Wisconsin–Madison  
600 Highland Avenue, K4/312 CSC  
Madison, WI, 53792  
Tel: 608-263-5009; Fax: 608-263-5316 (or 263-9947)  
E-mail: mehta@mail.humonc.wisc.edu  
web: www.radiotherapy.wisc.edu

**LICENSURE:** Wisconsin, Illinois

**BOARD CERTIFICATION:** American Board of Radiology (Therapeutic)

**ACADEMIC EDUCATION:** M.B.Ch.B., University of Zambia  
B.Sc. (Human Biology) with Distinction, Univ. of Zambia

**POSTGRADUATE TRAINING:**

Instructor, Radiation Oncology, University of Wisconsin  
PG 1-4 and Chief Resident, Radiation Oncology, University of Wisconsin  
PG 1-2, Ndola Central Hospital, Zambia

**PROFESSIONAL SOCIETIES:**

American Association for Cancer Education  
American Brachytherapy Society  
American Medical Association  
American Radium Society  
American Society for Therapeutic Radiology and Oncology  
American Society of Clinical Oncology  
Indo American Cancer Congress  
International Stereotactic Radiosurgery Society  
International Association for the Study of Lung Cancer  
Society of Neuro-Oncology  
Wisconsin Society of Radiation Oncologists  
State Medical Society of Wisconsin

**FACULTY APPOINTMENTS:**

2002-Present	Professor, Human Oncology, UW-Madison Medical School
1998-Present	Chairman, Human Oncology, UW-Madison Medical School
1998-Present	Associate Professor, Neurological Surgery, UW-Madison Medical School
1997-1998	Interim Chairman, Human Oncology, UW-Madison Medical School
1996-1997	Vice-Chairman, Human Oncology, UW Madison Medical School
1994-2002	Associate Professor, Human Oncology, UW-Madison Medical School
1994-1997	Director, Radiation Oncology Residency Training, UW-Madison
1988-1994	Assistant Professor, Human Oncology, UW-Madison Medical School

**HOSPITAL APPOINTMENTS:**

1998-Present	Staff Physician, Meriter Hospital, Madison, WI
1998-Present	Staff Physician, Holy Family Hospital, Manitowoc, WI
1994-Present	Staff Physician, Freeport Memorial Hospital, Freeport, IL
1992-Present	Staff Physician, St. Clare Hospital, Monroe, WI
1991-Present	Staff Physician, Wausau Regional Hospital, Wausau, WI
1989-Present	Staff Physician, Beloit Memorial Hospital, Beloit, WI
1988-Present	Staff Physician, UW Hospital and Clinics, Madison, WI
1988-Present	Staff Physician, William S. Middleton Veterans' Hospital, Madison, WI

**TEACHING EXPERIENCE:**

Some proprietary information has been deleted.

1998-Present	UW ADAC Radiosurgery Course
1997-1999	UWCCC Associate Director for Education.
1996-1998	ASTRO Refresher Course: HDR Brachytherapy (Lung/Esophagus).
1995-Present	University of Florida LINAC Radiosurgery.
1995	UCSD Gamma Knife Workshop.
1993-1996	Annual UCLA Hands-On Radiosurgery Workshop.
1991	UW Stereotactic Radiotherapy Workshop.
1990-1999	UW Medical School Neoplasia Course, Co-Director.
1990-1998	Oncology Instructor, UW Radiation Therapy Technology School.
1990-1996	Director, Neuro-Oncology Tumor Board.
1990-1994	UW Radiation Therapy Technology School, Director.
1989-Present	Health Line Reviewer.

1988-Present	UW Medical School Neoplasia Course Faculty.
1988-Present	UW Lecturer for Advanced Medical Physics Course.
1988-1994	Reference Source for American College of Radiology.
1988-1990	UW Radiation Oncology Course, Chief Instructor.
1987-1997	Cancer Education Committee Summer Assistantship Program.
1987-1990	Consultant, ACS: WI/IA Cancer Information Service.
1986-1988	Anatomy Instructor, UW Radiation Therapy Technology School.
1984-Present	Resident/Medical Student Education, University of Wisconsin.

**AWARDS AND HONORS:**

2001	The 15 <sup>th</sup> Annual Simon Kramer Lecture
1998-2001	ASTRO: "Meet the Professors"
1999	Nick Khadiwala Award for Excellence in Neuro-Oncology
1989-2001	AMA Physicians' Recognition Award
1998-1999	The Best Doctors in America: Midwest Region
1998	ASTRO Presidential Categorical Course
1996	"Radiotherapy Teacher of the Year," University of Wisconsin
1996	The Best Doctors In America: Midwest Region
1995	Year Book of Oncology
1994	Dean's Teaching Award, University of Wisconsin
1993	"Most important papers", International Monitor in Oncology
1992	"Outstanding Article in the Field", Respiratory Diseases Digest
1992	ASTRO Travel Research Award: Karolinska Institute, Sweden
1990	"Radiotherapy Teacher of the Year," University of Wisconsin
1989	1990 Year Book of Otolaryngology
	Raymond Radunski Prize: Best Overall Graduate, School of Medicine;
	Merck, Sharpe and Dohme Prize: Best Graduate, Internal Medicine;
	Upjohns Prize: Best Graduate, Pediatrics; Hassim Lucas Prize: Best
	Graduate, Obstetrics and Gynecology, University of Zambia
	Billingsley Award: Best 6th Year Student, University of Zambia
	Highest Scoring B.Sc., School of Natural Sciences, University of Zambia
	Wildlife Conservation Prize: Best Biology Freshman; Kerry Gill Prize:
	Best Chemistry Freshman, University of Zambia

**GRANTS:**

1. 2002-2007 RTOG CA 21661-27-33: PI: --- Brain Tumor Committee Chair: Mehta M.
2. 2002-2004 GE CT-PET for Radiotherapy Treatment Planning. Principal Investigator: Mehta MP
3. 2002-2004 UWCCC Pilot Project: Subcellular localization of Gd for GdNCT. Co-Project Leader: Mehta MP.
4. 2002-2003 Phase II randomized trial of Whole Brain Radiotherapy plus Temozolomide or Placebo for Patients with Brain Metastases. PI: Mehta MP.
5. 2001-2006 P01 CA88960-01-05: Improving Cancer Outcome with Adaptive Helical Tomotherapy. PI, Project and Core Leader: Mehta MP.
6. 2001-2006 NCI P30 CA14520-29: UW Comprehensive Cancer Center Support Grant. PI: Niederhuber J, Imaging and Radiation Sciences Program, Program Leader: Mehta M., 10% effort and salary, \$17,302,845.
7. 2001-2004 NCI P20 CA01010-1-3: Wisconsin Interdisciplinary Molecular Imaging Center Grant. PI: Grist T, Collaborator, Steering Committee Member & Project Leader (Tomotherapy based on Functional MRI, Positron Emission Tomography and Chemical Shift Imaging and Cell proliferation: Molecular Affects of Radiation Therapy): Mehta MP, 2% effort, 0% salary, \$1,212,102.
8. 2001-2002 Pharmacocycles Phase II Motexafin Gadolinium for GBM. Mehta M.
9. 2001-2002 NCI R43 AR47728-01: ProDermaCel: Topical Protector Against Chemo/Radiotherapy. PI: Fahl W, Collaborator & Consultant: Mehta MP, 5% effort, \$ 99,475.
10. 2001-2006 NCI K12 CA87718-01: Training Grant, PI: Schiller J, Co-investigator: Mehta, M (Trainer), 5% effort, \$1,250,000
11. 2001-2002 ---: Subcellular localization of a novel Gd compound for Gadolinium Neutron Capture Therapy (GdNCT), PI: ---, Co-investigator: Mehta, M.
12. 2001-2001 ---Pilot Grant to Evaluate C-erb-B2 Expression in Malignant Glioma. PI: Mehta M. 1999-2004
13. ---: PI: ---, Study Chair & Committee Vice Chair: Mehta M.
14. ---Pilot Grant: Staging disease in patients with lung cancer using CT and PET. PI: ---, Co-PI: Mehta M.
15. 1999-2002 PI: ---, Brain Tumor Committee Chair: Mehta M.
16. 1999-2002 Pilot Grant: Advanced imaging technologies for brain tumor treatment planning. PI: ---, Co-PI: Mehta M.

17. 1999-2000 ---Research Fund: Development of a system for fractionated Stereotactic Radiotherapy/Tomotherapy to allow online patient repositioning. PI: ---, Co-PI: Mehta M.
18. 1999-2000 Multi-institutional analysis of radiosurgically treated brain metastases patients stratified by RTOG RPA Class, PI: Mehta M.
19. 1999-2000 ---: Novel Telomerase Inhibitors for Brain Tumor Therapy. PI: Mehta M.
20. 1999-2000 Grant: Temozolomide and cis-retinoic acid for malignant glioma. PI: Mehta M.
21. 1999 Summer Research Grant: QOL tools for patients with brain metastases. PI: Mehta M.
22. 1998-2002 NCI U01 CA62421-05-09: Consortium Therapeutic Studies of Primary CNS Malignancies. PI: Mehta M., 10% effort, \$294,408.
23. 1998-2002 NCI U01 CA-62491: Phase I Clinical Trials of Novel Anti-Cancer Therapies. PI: Wilding G, Co-PI: Mehta M., 5% effort, \$1,519,820.
24. 1998-2001 NCI P30 CA14520-26-29: UW Comprehensive Cancer Center Support Grant: PI: Niederhuber J, Radiation Oncology and Physics Program Leader: Mehta M., 10% effort and salary, \$10,393,187.
25. 1998-2000 NCI RO1 CA48902-09-11: Optimized Planning and Delivery of Radiotherapy. PI: Mackie TR, Co-Investigator Mehta M., 5% effort and salary, \$1,158,388.
26. 1998-2000 ---Technology Development Grant. PI: ---.
27. 1998-2000 ---Grant PCI-P120-9801: Phase III Randomized Trial of Gadolinium Texaphyrin. PI: Mehta M.
28. 1998-1999 ---Fellowship Grant PI: Mehta M.
29. 1998-1999 ---Grant: Development of WWW-based modules for Oncology Grand Rounds. Co-PI: Mehta M.
30. 1998-1999 ---Research Grant: Phase I study of Gemcitabine plus palliative radiation therapy for advanced lung cancer. PI: Mehta M.
31. 1998-1999 ---Grant: A Field Test of Brain Quality of Life Tools. PI: Mehta M.
32. 1998 ---Education Grant: Post-Mastectomy Radiation Therapy, ASTRO Consensus Conference, PI: Mehta M.
33. 1997-Active ---Research & Development Fund. Various agencies and Individuals. PI: Mehta M.
34. 1997-1999 ---Fractionated radiosurgery frame and phantom development. PI: Mehta M., equipment grant.

35. 1997-1998 ---Development Grant: Enhancement of WWW-aided Educational Tools for Neoplastic Diseases Course. PI: Mehta M.
36. 1997-1998 ---Educational Research and Development Grant: Impact of WWW-aided Educational Tools on Neoplastic Diseases Course Learning. PI: Mehta M.
37. 1997-1998 --- Grant: Utilization of MRI and MRA in Radiosurgery Treatment Planning. PI: Mehta M.
38. 1997-1998 ---: Phase Ib/II study of Gd-Texaphyrin and cranial radiation for brain metastases. PI: Mehta M.
39. 1997 --- Grant: Comparison of MRA and angiographic localization for AVM radiosurgery. PI: Mehta M.
40. 1996-1997 ---Grant: Kytril in Radiation Emesis, PI: Mehta M.
41. 1994-1997 NCI U01 CA-62421 01-04: Therapeutic Studies of Primary CNS Malignancies in Adults. PI: Mehta M., \$111,000.
42. 1995-1996 ---Clinical Oncology Training Fellowship Grant: PI: Mehta M.
43. 1994-1998 ---: PI: ---, Study Chair & Committee Vice Chair: Mehta M.
44. 1993-1998 NCI UO1 CA-62492 Clinical trials of Novel Anti-Cancer Therapies. PI: Stewart J, Co-PI: Mehta M., \$877,634.
45. 1993-1998 NCI CCG-WI 5U10 CA-05436. PI: Gaynon P, Co-PI: Mehta M., \$1,022,645.
46. 1993-1995 ---Nursing and Clinical Research Fellowship, PI: ---, Co-PI: Mehta M.
47. 1990-1995 ---: A Phase II Study of Cisplatin/Vinblastine and WR 2721 Plus Radiotherapy and WR 2721 in Patients with Locally Advanced Non-Small Cell Lung Cancer, PI: ---, Co-PI: Mehta M.
48. 1992-1993 --- Grant: Effects of rh-GCSF on Neutropenia Induced by Whole Abdominal Radiation Therapy, PI: Mehta M.
49. 1992 ----Research Grant: Radiosurgery, Mehta M.
50. 1990-1992 --- Grant: Fluosol as an Adjuvant to Combination Whole Brain Radiation Therapy and Stereotactic Radiosurgery in the Treatment of Metastatic Brain Tumors, PI: Mehta M.
51. 1989-1992 ---: Pilot Study of Cisplatin/Vinblastine and WR 2721 Plus Radiotherapy and WR 2721 in Locally Advanced Lung Cancer, PI: ---, Co-PI: Mehta M.
52. 1991 ---: MRA for AVM Radiosurgery Planning, PI: Mehta M., equipment grant.

53. 1990 ---Grant: Bronchioalveolar Lavage in Radiation-Associated Pneumonitis, PI: ---, Co-PI: Mehta M.
54. 1990 ---Grant: Pentoxifylline for Radiation Myelitis, PI: ---, Co-PI: Mehta M.
55. 1989-Active ---Research Fund, Various agencies/Individuals. PI: Mehta M
56. 1989-1990 --- Grant: Monoclonal Antibody for Early Detection of Colorectal Cancer, PI: Mehta M.
57. 1988-1990 --- Grant: Phase III Randomized Fluosol Head and Neck Study, PI: Mehta M.
58. 1988 ---: Oxygen Probe Study, PI: Mehta M.
59. 1987-1988 ---: Acute Skin Reaction Study, PI: Mehta M.
60. 1986 ---: Radiolabeled Monoclonal Dosimetry, PI: Mehta M.

**CONSULTANT TO GRANTS:**

1. 1995 Breast Cancer Research: Low-cost, solid-state positron emission tomography imager for detection, diagnosis and staging of breast cancer. PI: ---.

**PENDING GRANTS:**

Proprietary information deleted.

**CLINICAL PROTOCOLS:**

1. MR spectroscopy of intracranial neoplasms. Co-Investigator.
2. Carrington Gel vs. no treatment, and Carrington Gel vs. aloe vera 98% gel in the prophylactic treatment of skin in patients receiving radiation therapy. Principal Investigator.
3. A prospective randomized study to evaluate the role of laser and/or conventional dose rate endobronchial irradiation (EBRT) for malignant airway obstruction. Principal Investigator.
4. A pilot study of Cisplatin/Vinblastine and WR 2721 plus radiotherapy and WR 2721 in patients with locally advanced non-small cell lung cancer. Co-Principal Investigator.
5. Fluosol-DA 20% as an adjuvant or radiation therapy in the treatment of advanced squamous cell carcinomas of the head and neck Phase III trial. Principal Investigator.
6. A prospective evaluation of intratumor oxygen tension prior to and during therapy with Fluosol-DA 20%. Principal Investigator.
7. Phase I testing of SEM-TEST and COTAKIT. Principal Investigator.
8. Evaluation of preoperative chemoradiotherapy in soft tissue sarcoma of the extremities. Co-Principal Investigator.

9. Fluosol as an adjuvant to stereotactic radiosurgery in the treatment of solitary brain metastases, a controlled Phase II Study. Study Chairman and QA Physician.
10. A Phase II trial to assess the effects of recombinant human gCSF in neutropenia induced by whole abdominal radiation therapy. Co-Principal Investigator.
11. A Phase II open label multicenter study with Sprodiamide injection in patients with malignant brain tumors following treatment with surgery, radiation and/or chemotherapy for the detection of viable tumor. Co-Investigator.
12. CO 9042 (NCI: T94-0099): Phase I study of topotecan and thoracic radiation. Radiotherapy Chair.
13. CO 9052: A Phase II study of Cisplatin/Vinblastine and WR 2721 radiotherapy and WR 2721 (ethyol) in patients with locally advanced non-small cell lung cancer. Co-Principal Investigator.
14. CO 9392 (NCI:T93:0059): A Phase I study of iododeoxyruidine and accelerated hyperfractionated radiotherapy for high grade gliomas. Study Chairman.
15. Phase II study of continuous infusion BCNU and cisplatin and external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme. Radiotherapy Co-Chair.
16. Phase II study of hyperfractionated accelerated radiation therapy for advanced unresectable non-small cell lung cancer. Principal Investigator.
17. NABTC 9401 (NCI T93-0057): A Phase II study of taxol chemotherapy for recurrent malignant glioma. Co-Investigator.
18. Phase III intergroup randomized comparison of radiation alone vs pre-radiation chemotherapy for pure and mixed anaplastic oligodendroglioma. ECOG Study Coordinator.
19. NABTC-9402 (NCI T94-0087): A Phase II trial of phenylacetic acid (PAA) for recurrent malignant glioma; a clinical and pharmacokinetics study of the North American Brain Tumor Consortium. Co-Investigator.
20. A Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation therapy with radiation therapy and concurrent adjuvant BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme. Radiotherapy Co-Chair.
21. NABTC 9403 (NCI T94-0184): A Phase I/II study of Paclitaxel (Taxol) chemotherapy for recurrent malignant glioma. Co-Investigator.
22. NABTC 9404 (NCI T95-0034): A Phase I trial and pharmacokinetic study of the sequential administration of Carmustine (BCNU) and Temozolomide in patients with CNS or systemic tumors refractory to standard chemotherapy. Co-Investigator.
23. Phase I study of topotecan and involved field radiation therapy for intrinsic pontine glioma of childhood. Radiation Therapy Chair and Study Vice-Chair.



24. A double-blind, parallel, multicenter study comparing the safety and efficacy of Kytril (granisetron hydrochloride) tablets 2 mg once daily with placebo in the prophylaxis of nausea and emesis in patients receiving fractionated upper abdominal radiotherapy for malignancy. Co-Investigator.
25. A pilot study of radiosurgery for recurrent brain tumors. Co-Investigator.
26. A group-wide pilot study of neoadjuvant chemotherapy followed by craniospinal hyperfractionated radiotherapy in patients with newly diagnosed high risk primitive neuroectodermal tumors (PNET). Co-Investigator.
27. A Phase II trial of Bryostatins in patients with recurrent high grade astrocytomas or mixed gliomas. Institutional Chair.
28. A Phase IB/II study of Gadolinium Texaphyrin and cranial radiation in patients with brain metastases. Institutional Chair.
29. A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas. Co-Investigator.
30. NABTC 9702 (NCI T96-0103): A Phase I trial of Pre-Surgical O<sup>6</sup>-Benzylguanine for malignant glioma. Co-Investigator.
31. Induction Paclitaxel and Carboplatin followed by standard radiotherapy (64 Gy/7 weeks) vs. continuous hyperfractionated accelerated radiotherapy (57.6 Gy/2.5 weeks) for patients with unresectable stage IIIA and IIIB non small cell lung cancer. Co-Chair.
32. A Phase II Trial of Thymidine and Carboplatin for recurrent malignant gliomas. Co-Principal Investigator.
33. A Phase II trial of preradiation multiagent chemotherapy for adults with "poor risk" medulloblastoma, PNET, and disseminated ependymoma. Radiotherapy Chair.
34. Phase I pilot trial of adenovirus p53 and radiotherapy on nonsmall cell lung cancer. Co-Chair.
35. A group-wide pilot study of concurrent carboplatin, vincristine and radiotherapy followed by adjuvant chemotherapy in patients with newly diagnosed high-risk central nervous system PNET and embryonal tumors. Co-Investigator.
36. A Phase II study of radiosurgery for patients with 1-3 newly diagnosed brain metastases from melanoma, renal cell carcinoma or sarcoma. Study Chair.
37. A Phase I study of Gadolinium Texaphyrin and cranial radiation in children with brainstem glioma. Study Chair.
38. Phase I study of Gemcitabine plus palliative radiation therapy for advanced lung cancer. Chair.
39. A Field Test of Brain Quality of Life Tools. Study Chair.

40. Randomized Phase III Trial of Gadolinium Texaphyrin (Gd-Tex) as a Radiation Sensitizer for Patients with Brain Metastases Undergoing Whole Brain Radiation, Co-Chair.
41. A Phase II study of observation in favorable low-grade glioma and a Phase III study of radiation with or without PCV chemotherapy in unfavorable low-grade glioma. ECOG Radiation Oncology Chair.
42. Phase II evaluation of Flavopiridol for treatment of recurrent or progressive malignant gliomas. Co-Investigator.
43. Phase I/II trial of Irinotecan (CPT-11) for recurrent malignant glioma. Co-Investigator.
44. Phase II Trial of Chemotherapy Plus Radiotherapy for Management of Primary Central Nervous System Non-Hodgkin's Lymphoma (PCNSL). Co-Chair.
45. CO 99501, NCI T98-0093: Pilot and Safety Trial of Carboplatin, Paclitaxel and Thalidomide followed by definitive radiotherapy in Advanced Non-small Cell Lung Cancer. Co-Chair.
46. Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, with or without Thalidomide, in patients with Stage III NSCLC. Co-Chair.
47. Staging Disease in Patients with Lung Cancer Using CT and PET. Co-Chair.
48. Phase II evaluation of Temodar and 13-Cis-Retinoic acid for progressive and recurrent malignant gliomas. Co-Investigator.
49. A Phase I/II randomized study of radiation therapy and temozolomide versus radiation therapy and BCNU versus radiation therapy and temozolomide and BCNU for anaplastic astrocytoma. ECOG Radiotherapy Chair.
50. A Phase I/II trial, SU5416, in patients with recurrent high grade astrocytoma or mixed gliomas. Co-Investigator.
51. A Phase II evaluation of temozolomide and thalidomide for treatment of recurrent and progressive glioblastoma multiforme. Co-Investigator.
52. A Pilot Study Investigating the Potential Value of Respiratory-Gated Radiotherapy in Lung Cancer: A University of Wisconsin Tomotherapy Group Study. Chair.
53. A Phase II Pilot Randomized Double-Blind Placebo Controlled Trial of Temozolomide and Radiation Therapy in the Treatment of Non-small Cell Lung Cancer Brain Metastasis. Chair.
54. Phase II trial of Motexafin Gadolinium and Cranial Irradiation in the treatment of newly diagnosed glioblastoma multiforme. Chair.
55. A Phase II trial of high dose tamoxifen for the treatment of newly diagnosed supratentorial glioblastoma multiforme (GBM). Radiotherapy Chair.
56. Phase I/II trial of R115777 in patients with recurrent malignant glioma. Co-Investigator.

57. An Observational Follow-Up Trial to Collect Survival Data on Patients Enrolled in Clinical Study PCI-P120-9801. Chair.
58. A Phase II evaluation of Fenretinide as a single agent in the treatment of adult patients with recurrent malignant glioma. Co-Investigator.
59. A Phase I/II trial of CPT-11 and temzolomide in patients with recurrent malignant glioma. Co-Investigator.
60. A Phase I/II trial of STI-571 in patients with recurrent malignant glioma and meningioma. Co-Investigator.
61. A Phase II Study to Evaluate the Effect of Dalteparin® (5,000 IU Subcutaneously) on clinically relevant Thromboembolic events and Survival When Administered Daily to Patients with Newly Diagnosed Glioblastoma Multiforme Receiving Radiation as Initial Therapy. Study co-chair.
62. A Phase I/II trial of ZD 1839 in patients with recurrent malignant glioma. Co-Investigator.
63. A Phase I/II trial of weekly infusion CCI-779 in patients with recurrent malignant glioma. Co-Investigator.
64. A Phase I/II trial of ZD 1839 and temozolomide in patients with recurrent malignant glioma. Co-Investigator.
65. Phase I trial of POH as a radiosensitizer with conventional XRT for the treatment of newly diagnosed glioblastoma multiforme. Co-Investigator.
66. Phase II study of Rofecoxib for the treatment of glioma associated edema. Investigator.
67. UW MegaVoltage Computed Tomography for Lung Cancer: A Feasibility Study. Investigator.
68. Phase II Trial of Poly-ICLC for Glioblastoma. Co-Investigator
69. Proprietary information deleted.
70. Proprietary information deleted.
71. Proprietary information deleted.
72. Proprietary information deleted.

**COMMITTEES:****A. National:**

1. 1990-Present ECOG Lung Core Committee
2. 1991-2000 Childrens Cancer Group Brain Tumor Strategy Group
3. 1991-2000 Childrens Cancer Group Radiation Therapy Strategy Group
4. 1992 ASTRO ad-hoc Radiosurgery Advisory Committee
5. 1992-Present ECOG Radiotherapy Committee
6. 1993-1996 ECOG Brain Tumor Working Group, Co-Chairman
7. 1993-Present ABS Clinical Research Committee Vice-Chairman
8. 1994 ECOG Scientific Advisory Committee
9. 1994-1999 Childrens Cancer Group Glioma Working Group
10. 1994-2000 Childrens Cancer Group Radiotherapy Steering Committee
11. 1996-Present ECOG Brain Tumor Committee, Vice-Chairman
12. 1996-Present ECOG Radiotherapy Toxicity Monitor
13. 1997-1999 ASTRO Membership Committee
14. 1997-Present ASTRO Education Committee
15. 1997-Present ASTRO School of Radiation-Oncology Vice Chair
16. 1997-Present ISRS Executive Committee
17. 1997-2001 Ad hoc FDA Technology Assessment Committee member
18. 1998-Present RTOG Brain Tumor Committee, Chairman
19. 1999-Present ABS Nominations Committee
20. 1999-Present ACRIN-RTOG Committee
21. 2000-Present American Joint Committee on Cancer (AJCC) CNS Task Force Committee
22. 2000 NIH Brain Tumor Progress Review Group
23. 2000-2001 AANS Joint Section on Tumors: Malignant Glioma Guidelines Committee
24. 2001-2006 RTOG Outcomes Committee Brain Tumor Liason
25. 2001-2004 American Brain Tumor Association Scientific Advisory Board
26. 2001-2005 FDA Radiological Devices Panel member
27. 2001-Present Childrens Oncology Group Central Nervous System Tumor Committee
28. 2001-Present Patterns of Care Outcomes Committee

29. 2001-Present American Board of Radiology Examinations Committee

B. Regional:

1. 1989-1992 Midwestern Neuro-Oncology Group Committee
2. 1996-Present WI State Medical Society Governmental Affairs Commission

C. Local:

1. 1988-Present Neuro-Oncology and Radiosurgery, University of Wisconsin
2. 1988-1991 PhD. Thesis Committee (Med Physics) Doug Simpkins, University of WI
3. 1989-1997 Radiation Oncology Special Procedures, University of Wisconsin
4. 1989-1991 Radiation Oncology Quality Assurance, University of Wisconsin
5. 1990-1991 Radiation Oncology CT Committee, University of Wisconsin
6. 1990-1994 Radiation Therapy Technology School Committee & Director
7. 1990-1996 UWCCC Surgical Oncology Committee
8. 1990-Present Combined Lung Cancer Committee, University of Wisconsin
9. 1991-1996 UWCCC Immunology and Biotherapeutics Committee
10. 1991-1998 COMS Group, University of Wisconsin
11. 1993-1995 Group Practice Steering Committee
12. 1993-1997 Ph.D. Thesis Committee (Medical Physics) Todd McNutt, University of WI
13. 1994-1996 Medical Board, University of Wisconsin Hospital and Clinics
14. 1994-Present Mentor Committee, Peter Mahler, MD, Human Oncology
15. 1994-Present Mentor Committee, Darryl Barton, MD, Human Oncology
16. 1995-1996 University of Wisconsin Hospital Council of Faculty
17. 1995-1997 UW Hospital Council of Residency Program Directors
18. 1995-2000 Mentor Committee, Judy Stitt, MD, Human Oncology
19. 1995-Present Department of Human Oncology Computer Committee
20. 1996-1997 University of Wisconsin, Radiology Chair Search Committee
21. 1996-1997 Department of Human Oncology, R&D Committee Chair
22. 1997-Present UWCCC Senior Leaders' Committee
23. 1997-2000 UW Medical School 1st and 2nd year Course Directors' Committee
24. 1997-Present Medical Board, University of Wisconsin Hospital and Clinics
25. 1997-1999 Radiation Oncology Technology Development Committee

26. 1997-1999 UW Ambulatory Cancer Center Strategic Planning Committee
27. 1997-1998 UW Ambulatory Cancer Center Multidisciplinary Clinics Planning Committee
28. 1997-1998 UW Ambulatory Cancer Center Radiation Oncology Planning Committee
29. 1997 UW Department of Radiology Chair Search Committee
30. 1997-1999 UWCCC Associate Director for Education
31. 1997- Present University of Wisconsin Hospital Council of Chairs
32. 1997-Present Mentor Committee, Behnam Badie, MD, Neurosurgery
33. 1998-1999 Dean's Teaching Award Selection Committee
34. 1998-Present UW Department of Neurological Surgery Executive Committee
35. 1998-2000 Mentor Committee, William Hunter, M.D., Neurosurgery
36. 1998-Present Mentor Committee, Rupak Das, Ph.D., Human Oncology
37. 1998-Present Mentor Committee, Wolfgang Tome, Ph.D., Human Oncology
38. 1998-Present Mentor Committee, Steven Howard, M.D., Ph.D., Human Oncology
39. 2000 Meriter Hospital Tumor Board, Committee Co-Chair
40. 2000 Ph.D. Thesis Committee (Medical Physics) Jeff Kapatoes, Uni of WI
41. 2001 PhD Thesis Committee (Med Phys): Chaun Wu, Uni of WI
42. 2001-Present UW Hospital Credentials Committee
43. 2001-2002 UW Vet School Search Committee
44. 2001-2002 Dean's Committee on Strategic Planning for Cancer

D. Private:

1. 1990 Alpha Therapeutics Corporation: Oncology Advisory Board
2. 1992-Present Editorial Board, Advanced Medical Publishing
3. 1998 Consultant, Pharmacyclics
4. 1998-2000 ALZA Radiation Oncology Advisory Board
5. 1999-2000 Schering-Plough, Temodar Advisory Board
6. 2000-Present ProCertus BioPharm Advisory Board
7. 2001-Present Chair, Medical Advisory Board, TomoInc
8. 2001-Present MedImmune Radiation Oncology Advisory Board
9. 2001-Present Ultravistal Medical Advisory Board
10. 2001-Present Philips Radiation Oncology Systems Medical Advisory Board

E. Invited Journal Reviewer:

1. American Journal of Neuroradiology
2. Archives of Ophthalmology
3. Cancer
4. Cancer Journal from Scientific American
5. Cancer Letter
6. Chest
7. Childrens' Cancer Group Manuscripts
8. Endocurietherapy Hyperthermia Oncology
9. International Journal of Radiation Oncology Biology Physics
10. Journal of Clinical Oncology
11. Journal of the National Cancer Institute
12. Journal of Neuro-Oncology; Editorial Board & Reviewer
13. Journal of Radiosurgery; Editorial Board & Reviewer
14. Neuro-Oncology
15. Oncology: International Journal of Cancer Research and Treatment
16. Radiation Oncology Investigations
17. Radiation Therapy Oncology Group Publications
18. Radiology
19. Experimental Lung Research
20. International Journal of Cancer

F. Invited Moderator/Examiner:

1. Allegheny-Singer Research Institute Grant Reviewer, Pittsburgh, PA (April 1992).
2. Fourth International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison, WI (September 16-19, 1992).
3. Scientific Session (Stereotactic CNS Techniques) Moderator, 36th Annual Meeting of American Society for Therapeutic Radiology and Oncology, San Francisco, CA, October 3 1994.
4. Scientific Session (Stereotactic CNS Techniques) Moderator, 37th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Miami, FL, October 9 1995.
5. American Board of Radiology, 1996 Clinical Examination Writing Task Force, Thoracic Tumors.
6. American Board of Radiology, 1996 Clinical Examination Writing Task Force, CNS Tumors.

7. Scientific Panel (Stereotactic Radiation) Moderator, 38th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Los Angeles, CA, October 1996.
8. American Board of Radiology, 1997 Oral Board Examiner, Thoracic Tumors/Sarcomas.
9. American Board of Radiology, 1997 Clinical Examination Writing Task Force, Thoracic Tumors.
10. Fifth International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison, WI (September 10-13, 1997).
11. Scientific Poster Panel (Stereotactic Radiation) Moderator, 39th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Orlando, FL, October 1997.
12. American Board of Radiology, 1998 Clinical Examination Writing Task Force, Thoracic Tumors.
13. American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Breast Cancer), Convener, Pittsburgh, PA, September 1998.
14. Scientific Poster Panel (Stereotactic Radiosurgery) Moderator, 40<sup>th</sup> Annual Meeting of American Society for Therapeutic Radiology and Oncology, Phoenix, AZ, October 1998.
15. American Society for Therapeutic Radiology and Oncology, Scientific Panel Presidential Categorical Course: CNS Tumors (Brain Metastases), Phoenix AZ, October 1998.
16. Scientific Poster Panel (Radiobiology) Moderator, Annual Meeting of the Society of Neuro-Oncology, San Francisco, CA, November 1998.
17. American Board of Radiology, 1998 Clinical Examination Writing Task Force, Thoracic Tumors.
18. American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Lung Cancer), Convener, Washington, DC, September 1999.
19. American Board of Radiology, 1999 Clinical Examination Writing Task Force, Thoracic Tumors.
20. Medical Research Council of Canada, Clinical Trials Grant Peer Reviewer, 2000.
21. American Society of Clinical Oncology, Discussant (Lung Cancer), New Orleans, LA, May 2000.
22. American Board of Radiology, 2000 Clinical Examination Writing Task Force, Thoracic Tumors.
23. American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Endovascular Brachytherapy), Convener, New York, NY, September 2000.
24. Society of Neuro-Oncology, Annual Meeting, Scientific Program Chair, Chicago, IL, November 2000.



25. Society of Neuro-Oncology, Annual Meeting, Scientific Session Moderator (Epidemiology and Prevention), Chicago, IL, November 2000.
26. American Society of Clinical Oncology 2001 Education Editor: Abstract review on Current Research on Treatment of Non-Small Cell Lung Cancer.
27. American Society of Clinical Oncology, Poster Discussion Leader (CNS Tumors), San Francisco, CA, May 2001.
28. American Board of Radiology, 2001 Oral Board Examiner, Thoracic Tumors/Sarcomas.
29. Sixth International Conference on Dose, Time and Fractionation in Radiation Oncology, Co-Chair, Madison, WI (September 23-26, 2001).
30. American Brain Tumor Association, 2001 Peer Grant Reviewer.
31. American Board of Radiology, 2001 Clinical Examination Writing Task Force, Thoracic Tumors.
32. American Society for Therapeutic Radiology and Oncology, School of Radiation Oncology, Fall Symposium (Pelvic Cancers), Convener, San Francisco, CA, September 2001.
33. American Board of Radiology, 2002 Exam Writing Task Force, Thoracic Tumors.
34. American Brain Tumor Association, 2002 Peer Grant Reviewer.
35. American Association for Cancer Research Neuro-Tumor Club, 2002 Convener.
36. National Brain Tumor Foundation, 2002 Peer Grant Reviewer.
37. Johns Hopkins CNS Tumors Spore Grant External Consultant, 2002-3.
38. National Pediatric Brain Tumor Foundation External Consultant, 2002
39. St. Jude's Children's Hospital Radiation Oncology Program External Reviewer, 2002.
40. American Society for Therapeutic Radiology and Oncology, Annual Meeting Abstract Reviewer (Lung Cancer), 2002.

#### **PUBLICATIONS:**

1. Shahabi S, Mehta MP: The role of computerized tomography in dosimetric evaluation of endobronchial implants. *Endocurie/Hypertherm Oncol* 4:187-191, 1988.
2. Wiley Jr AL, Wirtanen GW, Mehta MP, Shahabi S, Ramirez G: Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-Fluorouracil infusion and radiation therapy. *Acta Oncol* 27:377-381, 1988.
3. Mehta MP, Langeland P, Bertelrud KL: Adult Wilms' tumor: Role of combined modality treatment. *Acta Oncol* 28:647-650, 1989.

4. Mehta MP, Goetowski P, Kinsella TJ: Radiation induced thyroid cancer, 1920-87: A vanishing problem? *Int J Radiat Oncol Biol Phys* 16:1471-1475, 1989.
5. Mehta MP, Shahabi S, Thomadsen BR, Uehling D, Kinsella TJ: A three-dimensional model for treatment planning of interstitial implants. *Endocurie/Hypertherm Oncol* 5:227-230, 1989.
6. Mehta MP: Normal tissue response: summary. *American Association of Physicists in Medicine Proceedings* 7:154-157, 1989.
7. Mehta MP, Shahabi S, Jarjour N, Kinsella TJ: Endobronchial irradiation for malignant airway obstruction. *Int J Radiat Oncol Biol Phys* 17:847-851, 1989.
8. Shahabi S, Mehta MP, Wiley Jr AL, Gehring MA, Olsen KJ, Vainio PA: Computed tomographic dosimetric planning for optimization of pelvic interstitial implants. *Endocurie/Hypertherm Oncol* 6:47-52, 1990.
9. Mehta MP, Shahabi S, Jarjour N, Steinmetz MC, Chosy L: Effect of endobronchial radiation therapy on malignant bronchial obstruction. *Chest* 97:662-665, 1990.
10. Frank L, Rowley L, Shanahan TG, Mehta MP: Technical aspects in the use of "belly boards" for small bowel minimization. *Medical Dosimetry*, 15:13-16, 1990.
11. Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank L, Gehring MA, Kubsad SS, Utrie PC, Kinsella TJ: Minimization of small bowel volume within treatment fields using customized "belly board" mold. *Int J Radiat Oncol Biol Phys* 19:469-476, 1990.
12. Mehta MP, Kubsad SS, Fowler JF, Verma AK, Hsieh JT, Kinsella TJ:  $^{90}\text{Y}$ -B72.3 against pancreatic cancer: Therapeutic, dosimetric and biological analysis. *Int J Radiat Oncol Biol Phys* 19:627-631, 1990.
13. Kubsad SS, Mackie TR, Gehring MA, Paliwal BR, Mehta MP, Kinsella TJ: Monte Carlo and convolution dosimetry for stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys* 19:1027-1035, 1990.
14. Mehta MP: Endobronchial irradiation: Is HDR better? *Int J Radiat Oncol Biol Phys* 19:1629, 1990.
15. Thomadsen BR, Shahabi S, Mehta MP, Buchler DA, Giese WL: Differential loadings of brachytherapy templates. *Endocurie/Hypertherm Oncol* 6:197-202, 1990.
16. Gehring MA, Mackie TR, Kubsad SS, Paliwal BR, Mehta MP, Kinsella TJ: A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning. *Int J Radiat Oncol Biol Phys* 21:491-500, 1991.
17. Shahabi S, Mehta MP, Kubsad SS, Robertson S, Giese WL: Technical modification of perineal templates to reduce rectal mucosal dose from pelvic interstitial brachytherapy. *Endocurie/Hypertherm Oncol* 7:57-61, 1991.

18. Bertelrud KL, Mehta MP, Shanahan TG, Utrie PC, Gehring MA: An immobilization and bowel displacement device for abdomino-pelvic radiotherapy. *Radiologic Technology* 62:284-287, 1991.
19. Rozental JM, Levine RL, Mehta MP, Kinsella TJ, Levin AB, Algan O, Mendoza M, Hanson JM, Schrader D, Nickles RJ: Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. *Int J Radiat Oncol Biol Phys* 20:1053-1060, 1991.
20. Mehta MP, Mackie TR, Levin AB, Gehring MA, Kubsad SS, Rozental JM, Kinsella TJ: Radiosurgery for brain metastases. *Contemporary Oncology* 1:12-19, 1991.
21. Mehta MP, Bastin KT, Wiersma SR: Treatment of Wilms' Tumor: Current recommendations. *Drugs* 42:766-780, 1991.
22. Mehta MP, Petereit DG, Chosy L, Harmon MW, Fowler JF, Shahabi S, Thomadsen BR, Kinsella TJ: Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. *Int J Radiat Oncol Biol Phys* 23:133-139, 1992.
23. Mehta MP: Endobronchial brachytherapy: Wither prescription point? *Int J Radiat Oncol Biol Phys* 23:251, 1992.
24. Bastin KT, Mehta MP: Lung cancer mortality in Wisconsin: Year 2001, the therapeutic challenge. *Wisconsin State Medical Journal* 91:343-347, 1992.
25. Rieger J, Mehta MP, Paliwal BR, Kubsad SS: Weight consideration in the use of cerrobend beam blocks. *Medical Dosimetry* 17:141-143, 1992.
26. Mehta MP, Rozental JM, Levin AB, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Defining the role of radiosurgery in the management of brain metastases. *Int J Radiat Oncol Biol Phys* 24:619-625, 1992.
27. Bastin KT, Mehta MP: Meningeal hemangiopericytoma: Defining the role for radiation therapy. *J Neuro Oncology* 14:277-287, 1992.
28. Petereit DG, Mehta MP, Turski PA, Levin AB, Strother CM, Mistretta CA, Mackie TR, Gehring M, Kubsad SS, Kinsella TJ: Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database. *Int J Radiat Oncol Biol Phys* 25(2):309-313, 1993.
29. Petereit DG, Mehta MP, Buchler DA, Kinsella TK: A retrospective review of nodal treatment for vulvar cancer. *American Journal of Clinical Oncology* 16:38-42, 1993.

30. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ: Acute changes in glucose metabolism after treatment: The effects of Carmustine (BCNU) on human glioblastoma multiforme. *J Neuro Oncology* 15:57-66, 1993.
31. Bastin KT, Mehta MP, Kinsella TJ: Thoracic volume radiation sparing following endobronchial brachytherapy. *Int J Radiat Oncol Biol Phys* 25:703-707, 1993.
32. Mehta MP, Petereit DG, Kubsad SS, Turski PA, Levin AB, Kinsella TJ: Radiosurgery for arteriovenous malformations based on magnetic resonance angiography. *AMPI Medical Physics Bulletin* 18:25-28, 1993.
33. Mehta MP, Petereit DG, Turski PA, Kinsella TJ: Magnetic resonance angiography: A three-dimensional database for assessing arteriovenous malformations. *J Neurosurg* 79:289-293, 1993.
34. Mehta MP, Kinsella TJ: Cavernous sinus cranial neuropathies: Is there a dose-response relationship for radiosurgery? *Int J Radiat Oncol Biol Phys* 27:477-480, 1993.
35. Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Inguino femoral radiation of N0N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. *Int J Radiat Oncol Biol Phys* 27:963-967, 1993.
36. Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Groin node radiation for vulvar cancer: Treatment planning must do more than scratch the surface: Nodal control sustained at greater than 90% with 40 months median follow-up. *Int J Radiat Oncol Biol Phys* 27:991, 1993.
37. Nag S, Abitbol A, Anderson L, Blasko J, Flores A, Harrison L, Hilaris B, Martinez A, Mehta MP, Nori P, Porter A, Rossman K, Speiser BL, Stitt JA, Syed N, Vikram B: Consensus guidelines for high dose rate remote brachytherapy (HDR) in cervical, endometrial and endobronchial tumors. *Int J Radiat Oncol Biol Phys* 27:1241-1244, 1993.
38. Larson DA, Bova FJ, Eisert D, Kline R, Loeffler JS, Lutz W, Mehta MP, Palta J, Schewe F, Schultz CJ, Shaw E, Wilson JF: Current radiosurgery practice: Results of an ASTRO survey. *Int J Radiat Oncol Biol Phys* 28:523-526, 1994.
39. Larson DA, Bova FJ, Eisert D, Kline R, Loeffler JS, Lutz W, Mehta MP, Palta J, Schewe F, Schultz CJ, Shaw E, Wilson JF, Lunsford LD, Alexander E, Chapman P, Coffey R, Friedman W, Harsh G, Maciunas R, Olivier A, Steinberg G, Walsh J: Consensus statement on stereotactic radiosurgery quality improvement. *Int J Radiat Oncol Biol Phys* 28:527-530, 1994.

40. Lunsford LD, Alexander E, Chapman P, Coffey R, Friedman W, Harsh G, Maciunas R, Olivier A, Steinberg G, Walsh J, Larson DA, Bova FJ, Eisert D, Kline R, Loeffler JS, Lutz W, Mehta MP, Palta J, Schewe F, Schultz CJ, Shaw E, Wilson JF: Consensus statement on stereotactic radiosurgery quality improvement. *Neurosurgery* 34:193-195, 1994.
41. Mehta MP, Masciopinto JE, Rozental JM, Levin AB, Chappell RJ, Bastin KT, Miles J, Turski PA, Kubsad SS, Mackie TR, Kinsella TJ: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. *Int J Radiat Oncol Biol Phys* 30:541-549, 1994.
42. Mehta MP: Glioblastoma multiforme: "Who should receive stereotactic boost therapy?" *Int J Radiat Oncol Biol Phys* 30:746, 1994.
43. Auchter RM, Mehta MP, Peters NE, Kitchen R, Thomadsen BR, Kinsella TJ: An original technique for surface mold high dose rate brachytherapy for Kaposi's sarcoma of the penis. *Endocurie/Hypertherm Oncol* 10:193-198, 1994 .
44. Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotactic radiosurgery for glioblastoma multiforme. *Streatactic & Functional Neurosurg* 63:233-240, 1994.
45. Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotaxic radiosurgery for glioblastoma: A final report of 31 patients. *J Neurosurg* 82:530-535, 1995.
46. Mehta MP, Noyes WR, Mackie TR: Linear accelerator configurations for radiosurgery. *Seminars in Radiation Oncology* 5:203-212, 1995.
47. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Kinsella TJ: Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. *Int J Radiat Oncol Biol Phys* 32:931-942, 1995.
48. Mehta MP, Schiller JH: Prognosis with asymptomatic pulmonary nodules. *JAMA* 274:358, 1995.
49. Mehta MP, Kinsella TJ: The physical, biological and clinical basis of radiosurgery. *Current Problems in Cancer* 19: 267-329, 1995.
50. Mehta MP, Kinsella TJ, Harari PM, Mahler PA, Petereit DG, Ritter MA, Steeves RA, Stitt JA: Manpower issues and training program directions in radiation oncology. *Int J Radiat Oncol Biol Phys* 34:970, 1996.
51. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell RJ, Friedman W, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP: A multi-institutional outcome and prognostic factor analysis of radiosurgery (RS) for resectable single brain metastases:. *Int J Radiat Oncol Biol Phys* 35:27-35, 1996.
52. Thomas AM, Ryner LN, Mehta MP, Turski PA, Sorenson JA: Localized 2-D *J*-resolved <sup>1</sup>H MR spectroscopy of human brain tumors *in vivo*. *JMRI* 6:453-459, 1996.

53. Prados MD, Schold CS, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM: Phase II study of Paclitaxel in patients with recurrent malignant glioma. *J Clin Onc* 14:2316-2321, 1996.
54. Lamond JP, Mehta MP, Boothman DA: The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation. *J Neuro Oncology* 30:1-6, 1996.
55. Kesava PP, Baker EH, Mehta MP, Turski PA: Staging of arteriovenous malformations using three-dimensional time-of-flight MR angiography and volume-rendered displays of surface anatomy. *Am J Roentgenol* 167:605-609, 1996.
56. Tannehill SP, Mehta MP, Kinsella TJ: Amifostine (WR 2721) and radiation therapy: Past, present and future. *Sem Oncol* 23:69-77, 1996.
57. Kesava PP, Perl J, Mehta MP, Warner T, Graves VB, Strother CM: Thorotrast-associated oropharyngeal hemorrhage-treatment by means of carotid occlusion with use of flow arrest and fibered coils. *J Vasc Intervent Radiol* 7:709-712, 1996.
58. Mehta MP, Kinsella TJ: What's New In Radiation Oncology? *Wisc Med J* 96:42-49, 1997.
59. Mehta MP: External beam radiation therapy: an effective tool to manage painful bone metastases. *Cancer Pain Update* 66:3-4, 1997.
60. Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella T, Schiller JH: Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small cell lung cancer: results of a Phase II trial. *J Clin Oncol* 15:2850-2857, 1997.
61. Mehta MP, Noyes WR, Craig B, Lamond JP, Auchter RM, French MC, Johnson MN, Levin AB, Badie B, Robins HI, Kinsella TK: A cost-effectiveness and cost-utility analysis of radiosurgery versus resection for single brain metastases. *Int J Radiat Oncol Biol Phys* 39:445-454, 1997.
62. Yao MS, Mehta MP, Boyett JM, Li H, Donahue B, Rorke LB, Zeltzer PM. The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A Phase III study in a high-risk patient population. *Int J Rad Onc Biol Phys* 38:469-476, 1997.
63. Mehta MP, Boyd T, Sinha P: The status of stereotactic radiosurgery for cerebral metastases in 1997. *J Radiosurg* 1:17-30, 1998.
64. Chappell R, Miranpuri S, Mehta M: Dimension in defining tumor response. *J Clin Oncol*, 16:1234, 1998.
65. Bastin KT, Mehta MP, Rogers P, Miles J, Gilchrist K: Spectrum of radiosurgically induced histopathologic changes correlated with radiographic changes, *J Radiosurg*, 1:201-211, 1998.

66. Chang SM, Kuhn JG, Rizzo J, Robins IH, Schold SC Jr, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados M: Phase I study of paclitaxel in patients with recurrent malignant glioma. A North American Brain Tumor Consortium Report. *J Clin Oncol* 16:2188-2194, 1998.
67. Mehta MP: Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine. *Sem Radiat Oncol* 8:14-16, 1998.
68. Mehta MP, Sinha P, Kanwar K, Inman A, Albanese M, Fahl, W: Evaluation of Internet-based Oncologic Teaching for Medical Students. *J of Cancer Education* 13:197-202, 1998.
69. Mehta MP, Tannehill SP, Adak S, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D: Phase II trial of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer: Results of Eastern Cooperative Oncology Group trial 4593. *J Clin Oncol*, 16:3518-3523, 1998.
70. Kesava P, Mehta MP: MR demonstration of arterial thrombosis following radiosurgery for cerebral AVMs. *J Radiosurgery*, 1:291-295, 1998.
71. Mackie TR, Balog J, Ruchala K, Shepard D, Aldridge S, Fitchard E, Reckwerdt P, Olivera G, Mehta M: Tomotherapy. *Sem Rad Oncol*, 9:108-117; 1999.
72. Chang SM, Kuhn JG, Robins HI, Schold CS, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD: Phase II study of Phenylacetate in patients with recurrent malignant glioma. A North American Consortium Report. *J Clin Oncol*, 17:984-990, 1999.
73. Mehta MP: Amifostine and combined-modality therapeutic approaches. *Sem Oncol* 26:95-101, 1999.
74. Corn BW, Mehta MP, Buatti JM, Wolfson AH, Greven KM, Kim RY, Dunton CJ, Loeffler JS. Stereotactic Irradiation: potential new treatment method for brain metastases resulting from ovarian cancer. *Amer J Clin Onc* 22:143-146, 1999.
75. Mehta MP, Sanghavi S: Management Trends for Lung Cancer. *WI Med J*, 98:37-42, 1999.
76. Robins I, Tutsch K, Katschinski D, Jacobson E, Mehta M, Olsen M, Cohen J, Tiggelaar C, Arzooonian R, Albert D, Feierabend C, Wilding C: A Phase I Trial of Intravenous Thymidine and Carboplatin in Patients with Advanced Cancer. *J Clin Oncol* 17:2922-2931, 1999.
77. Sanghavi S, Skrupsky R, Badie B, Robins H, Tome W, Mehta M: Recurrent malignant gliomas treated with radiosurgery. *J Radiosurgery* 2:119-125, 1999.
78. Miranpuri SS, Schulz CA, Chappell RJ, Kesava PP, Nguyen PH, Olsen MA, McNutt TR, Mehta MP: Comparison of methods for response analysis of central nervous system neoplasms. *J Radiosurgery* 2:153-162, 1999.
79. Boyd TS, Mehta M: Stereotactic radiosurgery for brain metastases. *Oncology* 13:1397-1407, 1999.

80. Orth RC, Sinha P, Madsen EL, Frank G, Korosec FR, Mackie TR, Mehta MP: Development of a unique phantom to assess the geometric accuracy of magnetic resonance imaging for stereotactic localization. *Neurosurgery* 45(6):1423-1429, 1999
81. Gentry J, Boyd T, Mehta M: Use of digital technology improves patient documentation and decreases costs in radiation oncology. *J Oncology Mgmt*, 8:10-13, 1999.
82. Boyd T, Mehta MP: Radiosurgery for brain metastases: *Neurosurgery Clinics of North America* 10(2):337-350, 1999.
83. Schold Jr SC, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium Study. *Neuro-Oncology* 2:34-39, 2000.
84. Tome W, Mehta M, Paliwal B: From Roots to Realizations—Radiosurgery. *Advance for Admin in Rad & Rad Oncol*, 45-50, 2000.
85. Robins HI, Howard SP, Mehta MP: Validity of Datasets Questioned in Gliadel Study. *Letters to the Editors, Managed Care & Cancer*, pp 10-11, July/Aug 2000.
86. Mehta M, Tome W, Olivera G: *Neruo-Oncology: Radiotherapy of Brain Tumors. Current Oncology Reports*, 2:438-446, 2000
87. Merchant JJ, Kim K, Mehta MP, Ripple GM, Larson ML, Brophy DJ, Hammes LC, Schiller JC: Pilot and Safety Trial of Carboplatin, Paclitaxel and Thalidomide in Advanced Non-Small Cell Lung Cancer, *Clinical Lung Cancer* 2:48-52, 2000.
88. Gentry J, Steeves R, Paliwal B, Mehta M: The operational impact of a program to measure and monitor radiation dose to external beam patients. *J Oncology Mgmt*, 9:10-15, 2000.
89. Mehta MP: The Contemporary Role of Radiation in the Management of Lung Cancer: *Surgical Oncology Clinics of North America*, 9(3):539-561, 2000.
90. Gilbert M, O'Neill A, Gorssman S, Grunnet M, Mehta M, Jubelirer S, Hellman R: A Phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: An Eastern Cooperative Oncology Group Study (E2393). *J Neuro Oncol* 47:145-152, 2001.
91. Mehta M, Scrimger R, Mackie TR, Paliwal B, Chappell R, Fowler J: A New Approach to Dose Escalation in Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*, 49:23-33, 2001.
92. Chang SM, Kuhn JG, Robins, HI, Schold Jr. SC, Spence AM, Berger MS, Mehta MP, Pollack I, Rankin C, Prados MD: A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. *A North American Brain Tumor Consortium Report, Cancer*, 91:417-422, 2001.



93. Schulz CA, Harari PM, Mehta MP: Multiple daily fractionation radiotherapy schedules in lung cancer. *Current Oncology Reports*, 3:179-184, 2001.
94. Carde P, Timmerman R, Mehta M, Koprowski C, Ford J, Tishler R, Miles D, Miller R, Renschler M: Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients with Brain Metastases. *J Clin Oncol*, 19: 2074-2083, 2001.
95. Rao R, Robins HI, Mehta MP: An unusual case of liver metastases from GBM following radiosurgery. *J Radiosurgery* 3: 165-167, 2001.
96. de Stasio G, Casalbore P, Gilbert B, Mercanti D, Ciotti MT, Larocca LM, Rinelli A, Perret D, Mogk DW, Perfetti P, Mehta MP, Pallini R: Gadolinium in human glioblastoma cells for Gadolinium Neutron Capture Therapy (GdNCT). *Ca Res* 61:4272-77, 2001.
97. Auchter R, Scholtens D, Adak S, Wagner H, Cella D, Mehta MP: Quality of Life Assessment in Advanced Non-Small Cell Lung Cancer Patients Undergoing an Accelerated Radiotherapy Regimen: Report of ECOG Study 4593. *Int J Radiat Oncol Biol Phys*, 50: 1199-1206, 2001.
98. Sanghavi S, Miranpuri S, Chappell R, Buatti J, Mabanta S, Suh J, Regine W, Weltman E, Sneed P, Goetsch S, Breneman J, Sperduto P, Freedman W, Mehta M: Survival of brain metastases patients treated with radiosurgery and stratified by Recursive Partitioning Analysis: A Multi-institutional study. *Int J Radiat Oncol Biol Phys*, 51: 426-434, 2001.
99. Miranpuri AS, Tomé W, Paliwal B, Kesslering C, Mehta M: An Assessment of Operator-Induced Error for a Non-Invasive Frame for Fractionated Stereotactic Radiotherapy. *Int J Ca, Radiat Oncol Invest*, 96: 320-325, 2001.
100. Tome WA, Meeks SL, McNutt TR, Buatti JM, Bova FJ, Friedman WA, Mehta M: Optically guided intensity modulated radiotherapy. *Radiother Oncol* 61:33-44, 2001.
101. Rao R, Robins I, Mehta M: Late recurrence of a primitive neuro-ectodermal tumor. *Oncology* 61:189-191, 2001.
102. Mehta M, Yung A, Bullard D, Barger G, Choucair A, Gillin M, Grossman S, Guha A, Hammond E, Michalski J, Prados M, Provins S, Scott C, Zamorano L: Radiation Therapy Oncology Group Research Plan 2002-2006, Brain Tumor Committee. *Int J Rad Oncol Biol Phys* 51 (S2):11-18, 2001.
103. Hammond ME, Ang K, Byhardt R, Campbell B, Chapman JD, Eisenberg B, Greven K, Harris J, Hoffman J, Lange C, McCormick B, Mehta M, Sandler H, Trotti, A, Willet C, Wolfson A, Furness A, Jensen T, Grignon D, Okunieff P. Radiation Therapy Oncology Group Research Plan 2002-2006. Tumor Utilization Committee. *Int J Radiat Oncol Biol Phys*. 51(S2):103-9, 2001.
104. Liu Z, Salamat MS, Hafez GR, Mehta M, Robins HI, Amoli RS, Tomic S: Pineal sarcoma. *Acta Neurochirur* 144:89-92, 2002.
105. HI Robins, G Lui, L Hayes, M Mehta: Trestuzumab for Breast Cancer Carcinomatous Meningitis. *Clinical Breast Cancer* 2(4):316, 2002.

106. Robins HI, Chang S, Prados MD, Yung A, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Cloughesy T, Junck L, Mehta M: A Phase II Trial of Thymidine and Carboplatin for Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. *Neuro-Oncol* 4:109-114, 2002.
107. Mehta M: Retrospective vs. randomized data: The prevalence of bias, in response to Drs. Millar and Lapierre. *Int J Rad Oncol Biol Phys*, 2002 (in press).
108. Mehta MP: Book Review: Combined Modality “Combined Modality Therapy of Central Nervous System Tumors” eds Brady, Heilmann and Molls, Springer, Berlin, Oncology , 2002 (in press).
109. Patel R, Mehta MP: 3-D conformal radiation therapy for lung cancer:promises and pitfalls. *Current Oncology Reports*, 2002 (in press).
110. Scrimger RA, Tome WA, Olivera GH, Reckwerdt PJ, Mehta MP, Fowler JF: Reduction in Radiation Doses to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements. *Am J Clin Oncol*, 2002 (in press).

111. Harari P, Mehta M, Ritter M, Petereit D: Clinical Promise versus Clinical Reality in the Delivery of Concurrent Chemoradiotherapy. Seminars in Radiation Oncology 2002 (in press).
112. Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, Regine WF, Weltman E, King VJ, Breneman JC, Sperduto PW, Mehta MP: A Multi-Institutional Review Of Radiosurgery Alone Vs. Radiosurgery With Whole Brain Radiotherapy As The Initial Management Of Brain Metastases. Int J Radiat Oncol Biol Phys, 2002 (in press).
113. TR Mackie, J Kapatoes, K Ruchala, W Lu, C Wu, G Olivera, L Forrest, W Tome, J Welsh, R Jeraj, P Harari, P Reckwerdt, B Paliwal, M Ritter, H Keller, M Mehta: Image-Guidance for Precise Conformal Radiotherapy. Int J Radiat Oncol Biol Phys, 2002 (in press).
114. Thomadsen B, Howard S, Mehta MP: Supine Craniospinal Setup for Pediatric Radiotherapy. Medical Dosimetry, 2002 (in press).
115. Herman M, Tremont I, Trask D, Froseth C, Meyer C, Renschler M, Mehta M: Neurocognitive tools for brain metastases patients: A pilot trial. Am J Clin Oncol (in press).
116. R J Packer, M Mehta. Neurocognitive Sequelae of Cancer Treatment (Editorial). Neurology 2002 (in press).
117. Regine WF, Sperduto PW, Mehta MP: What is the Appropriate *Primary* Endpoint for Clinical Trials for Patients With Brain Metastases: In Response to Dr. Burri and Asher. Int J Radiat Oncol Biol Phys, 2002 (in press).
118. Mehta MP, Shapiro W, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith J, Miller R, and Renschler MF: Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole Brain Radiation for Patients with Brain Metastases: Centralized Assessment of MRI, Neurocognitive and Neurologic Endpoints. J Clin Oncol, 2002 (in press).
119. Tomé W, Mehta M, Paliwal B: Advances in Stereotactic Radiosurgery and Fractionated Stereotactic Radiosurgery (submitted).
120. Sanghavi S, Needle M, Krailo M, Geyer R, Ater J, Mehta MP: CCG 0952; A Phase I Study of Topotecan, as a Radiosensitizer, for Brainstem Glioma of Childhood. J Neurooncol (submitted).

121. M Downs, C Nieder, MP Mehta, P Carde, R Timmerman, J Wittes, RA Miller, A DeVault, and MF Renschler: Motexafin Gadolinium for the Treatment of Brain Metastases: Favorable Survival Outcome in a Phase Ib/II Trial Compared to Matched Historical Controls. JNCI (submitted).
122. B Paliwal, J P Balog, T R Mackie, M P Mehta, M A Ritter, P M Harari, G H Olivera: Technical Aspects of the University of Wisconsin Tomotherapy Unit. J Applied Clin Med Phys (submitted).
123. Mehta MP, Abrey L: Treatment of Solid Tumor Brain Metastases: Current Modalities and Future Directions. Oncology (submitted).
124. Sperduto PW, Scott CB, Andrews D, Schell M, Werner-Wasik M, Demas W, MD, Ryu, JK, Gaspar L, Rotman M, Souhami L, Mehta MP, Curran WJ: A phase III prospective randomized trial of whole brain radiation therapy plus stereotactic radiosurgery versus WBRT alone in patients with 2-3 brain metastases: Initial report of Radiation Therapy Oncology Group protocol 95-08. NEJM (in submission).
125. Schulz C, Mehta MP, Kinsella TJ: A Phase I trial of continuous infusion Iudr and hyperfractionated, accelerated radiation therapy for malignant glioma. Int J Radiat Oncol Biol Phys (in submission).
126. Hong T, Hayes L, Rao R, Badie B, Robins I, Chappell R, Mehta M: Acute complications of radiosurgery. Radiat Oncol Invest (in submission).
127. Yao-Long M, Mehta MP, Donohue B, Zeltzer P, Boyett JM: Patterns-of-failure in supratentorial primitive neuro-ectodermal tumors treated on CCG 921, a Phase III combined modality study. J Clin Oncol (in submission).
128. Baker G, Tome W, Mehta MP: Definition of AVM nidus for radiosurgery using segmentation tools. J Radiosurgery (in submission)
129. Kesslering C, Renschler M, Vanel D, Mathews V, Rosenthal D, Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Miller R, Mehta M: Selective uptake and retention of the radiation sensitizer Gadolinium Texaphyrin (Gd-Tex) in tumors demonstrated by MRI in Phase I and Phase II clinical trials. Radiology (in submission).

#### **PUBLICATIONS–ABSTRACTS:**

1. Wiley Jr AL, Wirtanen GW, Mehta MP, Ramirez G: Prophylactic liver therapy with intra-arterial 5-FU and X-ray therapy. Proceedings of the 3rd International Conference on Advances in Regional Cancer Therapy. Neu-Ulm, West Germany, pp 40, 1987.
2. Thomadsen BR, Shahabi S, Buchler DA, Giese WL, Mehta MP: Differential loading of the brachytherapy template. Radiology 165(P):69, 1987.

3. Wiley Jr AL, Wirtanen GW, Mehta MP, Ramirez G: Prophylactic combined hepatic artery 5-Fluorouracil infusion and hepatic X-ray therapy for pancreatic carcinoma. *Digestive Diseases and Sciences* 32:1190, 1987.
4. Mehta MP, Kubsad SS, Verma AK, Kinsella TJ: An *in vivo* model for dosimetric analysis of radiolabeled monoclonal antibodies. *American Association of Cancer Research Proceedings* 29:429, 1988.
5. Goetowski P, Mehta MP, Stephenson J, Kinsella TJ: Radiation-induced thyroid cancer, 1920-1987: a vanishing phenomenon? *Int J Radiat Oncol Biol Phys* 15 (S1):139, 1988.
6. Mehta MP, Goetowski P, Shahabi S, Kinsella TJ: Endobronchial brachytherapy for malignant airway obstruction. *Int J Radiat Oncol Biol Phys* 15(S1):119, 1988.
7. Wiley Jr AL, Mehta MP, Wirtanen GW, Ramirez G: Chemoradiotherapy for unresectable biliary carcinoma. *Int J Radiat Oncol Biol Phys* 15 (S1):240, 1988.
8. Shahabi S, Mehta MP: The physics of endobronchial brachytherapy and the role of CT planning for 3-D dosimetry. *Phys Med Bio* 33(1):130, 1988.
9. Shahabi S, Kubsad SS, Mehta MP, Stephenson J, Kinsella TJ: A technique for partial shielding in pelvic interstitial implants. *Med Phys* 16:474 (P3-1), 1989.
10. Shahabi S, Mehta MP, Thomadsen BR, Kinsella TJ: Use of computerized tomographic dosimetric planning for optimization of pelvic interstitial implants. *Med Phys* 16:474 (P-3-2), 1989.
11. Mackie TR, Kubsad SS, Mehta MP, Misco D, Sohn W, Gehring MA, Paliwal BR, Loper D, Thomadsen BR, Shahabi S: Physical aspects of stereotactic radiotherapy using a linear accelerator. *Med Phys* 16:460 (E-7), 1989.
12. Shanahan TG, Mehta MP, Gehring MA, Buchler DA, Kubsad SS, Kinsella TJ: Minimization of small bowel volume utilizing customized "belly board" mold. *Int J Radiat Oncol Biol Phys* 17(S):187-18, 1989.
13. Gehring MA, Mackie TR, Kubsad SS, Paliwal BR, Mehta MP, Kinsella TJ: An improved ray casting technique for surface-shaded display: applications in radiation treatment planning. *Int J Radiat Oncol Biol Phys* 17(S):126, 1989.
14. Kubsad SS, Mackie TR, Gehring MA, Paliwal BR, Mehta MP, Kinsella TJ: Monte Carlo and convolution dosimetry for stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys* 17(S):196, 1989.
15. Mehta MP, Kubsad SS, Fowler JF, Kinsella TJ: Radioimmunotherapy: dosimetric and biological analysis. *Int J Radiat Oncol Biol Phys* 17(S):21, 1989.
16. Shahabi S, Mehta MP, Kubsad SS, Thomadsen BR, Kinsella TJ: Direct computerized tomographic (CT) dosimetry of endobronchial implants. *Int J Radiat Oncol Biol Phys* 17(S):239, 1989.

17. Mehta MP, Goetowski PG, Kinsella TJ: Radiation-induced thyroid neoplasms, 1920-1987: A vanishing problem? *Oncology Review: Late sequelae of cancer therapy in children and adolescents*, pp 56, October 1989.
18. Mehta MP, Steinmetz MC, Harmon MW, Kubsad SS, Gehring MA, Mackie TR: Brain tumor response following stereotactic radiotherapy. *American Society of Clinical Oncology Proceedings* 9:91, 1990.
19. Harmon MW, Mehta MP, Shahabi S, Steinmetz MC, Thomadsen BR, Fowler JF: Conventional versus hyperfractionated high dose rate endobronchial radiation. *Int J Radiat Oncol Biol Phys* 19(S):232-233, 1990.
20. Mehta MP, Steinmetz MC, Harmon MW, Kubsad SS, Mackie TR, Gehring MA, Levin AB, Kinsella TJ: Stereotactic radiation: Evaluation of brain tumor response. *Int J Radiat Oncol Biol Phys* 19(S):269, 1990.
21. Mehta MP, Petereit DG, Harmon MW, Shahabi S, Thomadsen BR, Fowler JF: Hyperfractionated high dose rate endobronchial radiation. *Endocurie/Hypertherm Oncol* 7:81, 1991.
22. Mehta MP, Schiller JH, Bastin KT, Kinsella TJ: Pilot study of WR 2721/CDDP/VLB and sequential TRT/WR 2721 in Stage III NSCLC: Preliminary results. *American Society of Clinical Oncology Proceedings* 10:263, 1991.
23. Mehta MP, Shanahan TG: "Belly board" for radiotherapy. *Contemporary Oncology* 1:60, 1991.
24. Gehring MA, Mackie TR, Sanders CL, Reckwerdt PJ, Kubsad SS, Mehta MP: 3-D visualization tools for stereotactic radiosurgery treatment planning. *Med Phys* 18:602 (E-1), 1991.
25. Thomadsen BR, Shahabi S, Buchler DA, Mehta MP, Paliwal BR: Anatomy of two high dose rate misadministrations. *Med Phys* 18:645 (P-45), 1991.
26. Mackie TR, Gehring MA, Reckwerdt PJ, Sanders CL, Mehta MP, Kubsad SS: A fast algorithm for dose computation and arc weighting for stereotactic radiosurgery. *Med Phys* 18:646 (P-48), 1991.
27. Harmon MW, Petereit DG, Mehta MP, Fowler JF, Shahabi S, Thomadsen BR, Kinsella TJ: Sequential comparison of LDR and hyperfractionated HDR EBRT for MAO. *Int J Radiat Oncol Biol Phys* 21(S):137-138, 1991.
28. Petereit DG, Mehta MP, Turski PA, Strother CM, Levin AB, Mackie TR, Gehring MA, Kinsella TJ: The role of magnetic resonance angiography in the radiosurgical management of arteriovenous malformations. *Int J Radiat Oncol Biol Phys* 21(S):196, 1991.
29. Mehta MP, Levin AB, Rozental JM, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys* 21(S):172, 1991.

30. Bastin KT, Mehta MP, Levin AB, Rozental JM, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Radiosurgery for gliomas. *Radiology* 181(P):139, 1991.
31. Bastin KT, Mehta MP, Kinsella TJ: Quantitative analysis of lung sparing following endobronchial boost in Stage III non-small cell lung carcinoma treated curatively. *Endocurie/Hypertherm Oncol* 7:225, 1992.
32. Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Is inguino-femoral irradiation as effective as lymphadenectomy for N0, N1 vulvar disease? *Int J Radiat Oncol Biol Phys* 24(S):145-146, 1992.
33. Mehta MP, Petereit DG, Harmon MW, Shahabi S, Thomadsen BR, Fowler JF: Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. *Respiratory Diseases Digest* 1:16-17, 1993.
34. Bastin KT, Mehta MP, VerHoeve JN, Chandra B, Thomadsen BR, Lipman R, Knudson K, Kinsella TJ: Selective optic nerve irradiation simulating radiosurgery: An animal model. *Proceedings of the 41st Annual Meeting of Radiation Research Society*, pg. 172 P-33-8, 1993.
35. Mehta MP, Thomas AM, Levin AB, Kinsella TJ: Preliminary analysis of multivoxel  $^1\text{H}$  MR spectroscopic imaging for CNS neoplasms. *Proceedings of 41st Annual Meeting of Radiation Research Society*, pg. 132 P-24-7, 1993.
36. Mehta MP, Storer B, Schiller JH: Phase II study of WR 2721/Cisplatin/Vinblastine, followed by thoracic radiation (TRT) and WR 2721, in Stage III non-small cell lung cancer (NSCLC). *American Society of Clinical Oncology Proceedings* 12:359, 1993.
37. Mehta MP, Werwie S, Levin AB, Kinsella TJ: Surgery vs radiosurgery for brain metastases. *Acta Neurochirurgica* 122:Fasc. 1-2, 157-158, 1993.
38. Levin AB, Mehta MP, Masciopinto JE, Rohde B: Stereotactic radiosurgery for glioblastoma multiforme. *Acta Neurochirurgica* 122:Fasc. 1-2, 154, 1993.
39. Bastin KT, Mehta MP, Rogers P, Miles J, Kinsella TJ: Correlation of post-radiosurgical tumor histopathology with radiographic changes. *Int J Radiat Oncol Biol Phys* 27 (S):152, 1993.
40. Mehta MP, Masciopinto JE, Bastin KT, Levin AB, Chappell RJ, Miles J, Kinsella TJ: Glioblastoma treated with external beam radiotherapy and stereotactic radiosurgery boost. *Int J Radiat Oncol Biol Phys* 27 (S):153, 1993.
41. Thomas AM, Khorsand M, Miles J, Levin AB, Sebree L, Bianco JA, Mehta MP, Puccetti DM, Turski PA, Javid MJ:  $^1\text{H}$  and  $^{31}\text{P}$  MR spectroscopy of human brain tumors *in vitro*. *Radiology* 189 (P): 393, 1993.
42. Schiller JH, Mehta MP, Larson M, Storer B, Reynolds R, Capizzi R: Amifostine, cisplatin and vinblastine for advanced non-small cell lung cancer. *Lung Cancer* 11:178, 1994.

43. Mehta MP, Storer B, Larson M, Kinsella TJ, Schiller JH: High response rate for advanced non-small cell lung cancer with amifostine, cisplatin, vinblastine and radiation. Proceedings of the American Society of Clinical Oncology 13:349,1994.
44. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Kinsella TK: Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 30:164-5, 1994.
45. Mehta MP, Rozental JM, Levin AB, Mackie TR, Kubsad SS, Gehring MA, Kinsella TJ: Defining the role of radiosurgery in the management of brain metastases. The International Monitor in Oncology, 1994.
46. Schiller JH, Storer B, Berlin JD, Wittenkeller J, Larson M, Pharo L, Larson M, Mehta MP, Reynolds R, Capizzi R: Amifostine, plus chemotherapy for advanced non-small cell lung cancer. Cancer Investigation 13 (Supplement 1):9-12, 1995.
47. Mehta MP, Larson M, Storer B, Schiller JH: Phase II clinical trial of amifostine, cisplatin, vinblastine (ACV) and radiation therapy (RT) for unresectable Stage III non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, 14:373,1995.
48. Baker EH, Sorenson JA, Mehta MP: Segmentation of the AVM nidus for radiosurgery planning. Proceedings of the 2nd Congress of the International Stereotactic Radiosurgery Society, 2:87-88, 1995.
49. Noyes WR, Mehta MP, Auchter RM, Lamond JP, Levin AB, Alexander E, Loeffler JS: Radiosurgery for single brain metastases: Outcome and cost analysis. Proceedings of the 2nd Congress of the International Stereotactic Radiosurgery Society, pp 57-58, 1995.
50. Mehta MP: An overview of the current status of outcomes measures in therapeutic radiology. Medical Physics 22:954, 1995.
51. Tannehill SP, Mehta MP, Larson M, Storer B, Schiller JH: Phase II clinical trial of amifostine (WR 2721), cisplatin (C), vinblastine (V) (ACV) and thoracic radiation therapy (RT) for unresectable Stage III non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 32:196, 1995.
52. Yao-Long M, Mehta MP, Donohue B, Zeltzer P, Boyett JM, Kinsella TK: Patterns-of-failure in CCG 921, a Phase III study of chemoradiotherapy in high-risk intracranial PNET. Int J Radiat Oncol Biol Phys 32:182, 1995.
53. Baker EH, Mehta MP, Sorenson JA: Definition of AVM nidus for radiosurgery using segmentation tools. Int J Radiat Oncol Biol Phys 32:285, 1995.
54. Mehta MP: Stereotactic radiosurgery: Metastatic brain lesions. Proceedings of the UCLA Fifth Annual Workshop on Minimally Invasive Therapy of the Brain pp 117-120, Santa Monica, CA, 1995.



55. Mehta MP, Masciopinto JE, Rozental JM, Levin AB, Chappell RJ, Bastin KT, Miles J, Turski PA, Kubsad SS, Mackie TR, Kinsella TJ: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Year Book of Oncology, 1995.
56. Kesava PP, Baker EH, Mehta MP, Turski PA: Pre-radiosurgery classification of AVMs using MRI 3-D time-of-flight MRA, anatomic surface rendering and phase contrast flow analysis. Proc Am Roentgen Ray Soc 95:81, 1995.
57. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell RJ, Friedman W, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP: A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastases. Int J Radiat Oncol Biol Phys 35:27-35, 1996.
58. Donahue B, Mehta MP, Prados MD, Allen J, Wara W, Newall J: Absence of radionecrosis following high-dose posterior fossa hyperfractionated radiotherapy for primitive neuroectodermal tumors. Proceedings of the 64th Annual Meeting of the American Association of Neurological Surgeons pp 212, 1996.
59. Chang SM, Schold CS, Spence AM, Berger MS, McAllister L, Mehta MP, Gilbert MR, Fulton D, Prados MD: Phase I/II study of Paclitaxel chemotherapy for recurrent malignant glioma: Preliminary report. North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology 15:153, 1996.
60. Prados MD, Spence AM, Schold CS, Robins HI, Mehta MP, Berger MS, Kuhn J, Rector D, Chang SM, Gilbert MR: A Phase II trial of phenylacetic acid for recurrent malignant glioma: Preliminary report of the North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology 15:156, 1996.
61. Berlin JD, Schiller JH, Hutson PR, Feierabend C, Simon K, Alberti D, Arzoomanian RZ, Boothman DA, Planchon S, Wuerzberger S, Glen V, Mehta MP, Wilding G: Phase I clinical and pharmacokinetic study of daily topotecan with thoracic irradiation. Proceedings of the American Association of Cancer Research 37:164, 1996.
62. Fahl WE, Holt RW, Mehta MP: Cancer education: Past, present and future. The pre-clinical oncology educational program at the University of Wisconsin. J Cancer Education 11:17, 1996.
63. Tannehill SP, Froseth C, Wagner H, Petereit DP, Mehta MP: A multi-institutional Phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer: Initial report of ECOG 4593. Int J Radiat Oncol Biol Phys 36:207, 1996.
64. Mehta MP: The current status of radiosurgery. Int J Radiat Oncol Biol Phys 36:112, 1996.

65. Mehta MP: Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. *Int J Radiat Oncol Biol Phys* 36:142, 1996.
66. Mehta MP, Rozental JM, Puccetti DM, Robins HI: Sequential combination chemotherapy and radiotherapy of malignant brain tumors in children and adults. *Cancer Invest* 15:10-11, 1997.
67. Tannehill SP, Mehta MP, Froseth C, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D: Phase II trial of hyperfractionated accelerated radiation therapy (HART) for unresectable non-small cell lung cancer(NSCLC): preliminary results of ECOG 4593. *Proceedings of the American Society of Clinical Oncology* 16: 446a,1997.
68. Schulz CA, Mehta MP, Robins HI, Badie B, Arzoomanian RZ, Simon K, Alberti D, Feierabend C, Kinsella TJ, Wilding G: A Phase I study of iododeoxyuridine and accelerated hyperfractionated radiotherapy for malignant gliomas. *Proceedings of the American Society of Clinical Oncology* 16:249a, 1997.
69. Kuhn JG, Rizzo J, Chang SM, Schold C, Spence AM, Berger MS, Robins HI, Mehta MP, Bozik ME, Fulton D, Rector D, Prados MD: Effects of anticonvulsants (ACs) on the pharmacokinetics (PK) and metabolic profile of paclitaxel. *Proceedings of the American Society of Clinical Oncology* 16: 224a, 1997.
70. Mehta MP, Tannehill SP, Martin L, Froseth C, Wagner H, Johnson D: ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for non-small cell lung cancer (NSCLC): Early results and RT quality assurance (QA). *Lung Cancer* 18:123, 1997.
71. Nag S, Abitbol A, Erickson B, Fontanessi J, Hilaris BS, Martinez A, Mehta M, Nori D, Orton C, Porter AT, Speiser B, Stitt J, Young D: Survey of brachytherapy practice for carcinoma of the cervix in the United States-a report of the American Brachytherapy Society (ABS). 19th Annual Brachytherapy Society Meeting Proceedings, pg 7, 1997.
72. Mehta MP: Radiation Pneumonitis: Clinical spectrum, molecular pathophysiology, treatment and prevention. 5th International Conference on Dose, Time and Fractionation in Radiation Oncology Meeting Proceedings, pg 29, 1997.
73. Schulz CA, Mehta MP, Robins HI, Badie B, Arzoomanian R, Simon K, Alberti D, Feierabend C, Kunugi KA, Wilding G, Kinsella TJ: Continuous 28 day iododeoxyuridine (IudR) and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: a phase I clinical and thymidine replacement study. *Int J Radiat Oncol Biol Phys* 37:139, 1997.
74. Boyd T, Mehta MP, Donohue B, Prados M, Allen J: Feasibility & acute toxicities of craniospinal hyperfractionated radiotherapy (CHFRT) for high-risk intracranial primitive neuroectodermal tumors (HRPNET); CCG 9931; a groupwide Phase II study of intensive chemoradiotherapy (CT) and CHFRT. *Int J Radiat Oncol Biol Phys* 37:144, 1997.

75. Mehta MP, Adak S, Wagner H, Cella D: Experience with the functional assessment of cancer therapy-lung (FACT-L) in ECOG 4593, a Phase II hyperfractionated accelerated radiation therapy (HART) trial. *Int J Radiat Oncol Biol Phys* 37:232, 1997.
76. Bastin KT, Mehta MP: Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: a rabbit model using visual evoked potentials, fundoscopy and histology. *Int J Radiat Oncol Biol Phys* 37:226, 1997.
77. Mehta MP: Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. *Int J Radiat Oncol Biol Phys* 37:123, 1997.
78. Mehta MP: Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on Amifostine. *Proceedings of Advances in Therapy: Protecting against the toxicities of radiotherapy*, pg 12, 1997.
79. Mehta MP, Sinha P, Fahl W, Kanwar K, Inman A: A randomized assessment of the value of Web-based education for teaching second year medical students. *J Cancer Education* 12 (S):27, 1997.
80. Mehta MP: Book Review: Principles and Practice of Radiation Therapy: Introduction to Radiation Therapy, CM Washington and DT Leaver (eds). *Med Phys* 24:929, 1997.
81. Chang S, Kuhn J, Schold C, Spence A, Berger M, Mehta M, Bozik M, Gilbert M, Robins I, Fulton D, Rankin C, Prados M: Phase I study of Paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Report. *Proceedings of the Society of Neuro-Oncology*, 1997.
82. Prados M, Rankin C, Kuhn J, Bozik M, Gilbert M, Spence A, Berger M, Mehta M, Robins I, Schold C, Chang S: Phase II study of Phenylacetate (PAA) in patients (pts) with recurrent malignant glioma (MG): a North American Brain Tumor Consortium report. *Proceedings of the Society of Neuro-Oncology*, 1997.
83. Nguyen P, Miranpuri S, Olsen M, Kesava P, Badie B, Mehta MP: Comparative assessment of response analysis techniques for CNS neoplasms. *Proceedings of the Congress of Neurological Surgeons*, 1997.
84. Carde P, Timmerman B, Koprowski D, Arwood J, Ford J, Larner J, Mehta M, Tishler R, Rosenthal D, Engel J, Miller M, Renschler M: Gadolinium-Texaphyrin (Gd-Tex) radiation sensitizer: improved survival in a Phase IB/II trial in patients with brain metastases. *Proceedings of the American Society of Clinical Oncology* 17:379a, 1998.
85. Kesslering C, Renschler M, Vanel D, Mathews V, Rosenthal D, Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Miller R, Mehta M. Selective uptake and retention of the radiation sensitizer Gadolinium Texaphyrin (Gd-Tex) in tumors demonstrated by MRI in Phase I and Phase II clinical trials. *Int J Radiat Oncol Biol Phys* 42:263, 1998.
86. Sanghavi S, Krailo M, Needle M, Geyer J, Ater J, Mosher R, Mehta M. Topotecan, as a radiosensitizer, for brainstem glioma (BSG) of childhood: First report of CCG 0952, a Phase I study. *Int J Radiat Oncol Biol Phys* 42:357, 1998.

87. Schulz C, Miranpuri S, Chappell R, Kesava P, Nguyen P, Olsen M, McNutt T, Mehta M. Comparison of methods for response analysis of central nervous system neoplasms. *Int J Radiat Oncol Biol Phys* 42:261, 1998.
88. Egorin M, Miles D, Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Mehta M, Miller R, Renschler M. Pharmacokinetics of the radiation sensitizer Gadolinium Texaphyrin in a Phase IB/II trial for patients with brain metastases receiving whole brain radiation. *Int J Radiat Oncol Biol Phys* 42:263, 1998.
89. Timmerman B, Carde P, Koprowski C, Arwood D, Ford J, Mehta M, Tishler R, Lerner J, Miller R, Koffler-Horovitz S, Hoth D, Renschler M. Phase IB/II trial of the radiation sensitizer Gadolinium Texaphyrin (Gd-Tex) for patients with brain metastases: Final results. *Int J Radiat Oncol Biol Phys* 42:198, 1998.
90. Schold C, Kuhn J, Chang S, Bosik M, Mehta M, Robins IH, Fink KL, Spence A, Fulton D, Rector D, Prados MD. A Phase I Trial of BCNU + Temozolomide: A North American Brain Tumor Consortium Study. Proceedings of the Society for Neuro-Oncology's 3<sup>rd</sup> Annual Scientific Meeting, 1998.
91. Harari PM, Kanwar K, Inman A, Kesslering C, Boyd T, Sanghavi S, Sinha P, Mehta M. Web-based multi-media modules for oncology grand rounds: Preliminary evaluation of listener satisfaction and knowledge gain. AACE 32<sup>nd</sup> annual meeting. *J Ca Edu*, 13:18, 1998.
92. Mehta M, Ford J, Carde P, Timmerman R, Renschler M. Gadolinium Texaphyrin (Gd-Tex), a tumor selective radiation sensitizer for primary and metastatic brain tumors. *Neuro-Oncology* 1:540, 1999.
93. Sanghavi S, Skrupky R, Badie B, Robins, I, Mehta M. Recurrent malignant gliomas treated with radiosurgery. Proceedings of the American Association of Neurological Surgeons 4<sup>th</sup> Annual Meeting, New Orleans, LA, # 1427, pg 245, April 1999.
94. Mehta MP: Pediatric Brain Tumors: Innovative therapeutic approaches-radiotherapy. Proceedings of the 4<sup>th</sup> International Symposium on Special Aspects of Radiotherapy: Controversies in Pediatric Oncology, Berlin, Germany, April 1999.
95. Needle MN, Mehta M, Krailo M, Geyer JR, Ater JL, Mosher R; The Children's Cancer Group, Arcadia, CA. Phase I Study of Topotecan as a Radiosensitizer Prior to Daily Involved Field Irradiation in Children with Intrinsic Pontine Glioma. A Children's Cancer Group Study. Proceedings of the American Society of Clinical Oncology, 18:558A, 1999.
96. Berlin JD, Schiller JH, Mehta MP, Hutson PR, Boothman DA, Alberti DB, Feierabend CA, Kehrli NJ, Binger KA, Kavka JE, Pomplun ML, Wahamaki AS, Storer B, Arzooonian RZ, Wilding G: Phase I study of topotecan and thoracic radiation. Proceedings of the American Society of Clinical Oncology, 18:175A, 1999.
97. Sanghavi SN, Miranpuri SS, Chappell R, Mabanta S, Suh JH, Regine WF, Weltman E, Sneed PK, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Buatti JM, Mehta MP: Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification. *Int J Radiat Oncol Biol Phys* 45:171, 1999.

98. Mehta MP, Meyers CA, Renschler MF, Eisenberg PD, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Arwood D, Cmelak AJ, Rao A, Brereton H, Timmerman RD, Phan SC, DeVault AR, Curran WJ, Gaspar L. Clinical trial of Gadolinium Texaphyrin (Gd-Tex) in patients with brain metastases. *Int J Radiat Oncol Biol Phys* 45:320, 1999.
99. Sanghavi S, Miranpuri SS, Chappell R, Buatti JM, Suh JH, Regine WF, Weltman E, Sneed PK, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Mehta M: Multi-institutional analysis of survival outcome for radiosurgery treated patients with brain metastases, stratified by RTOG RPA classification. *Neuro-Oncology* 1:337, 1999.
100. Robins IH, Mehta M, Chang S, Yung A, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Trask D, Prados MD. A Phase II Trial of Thymidine and Carboplatin for Recurrent Malignant Glioma: A North American Brain Tumor Consortium (NABTC) Study. Proceedings of the Society for Neuro-Oncology's 4<sup>th</sup> Annual Scientific Meeting, Scottsdale, AZ, November 1999.
101. Meyers CA, Mehta M, Eisenberg P, Schultz CJ, Ford JM, Roa W, Leibenhaut M, Phan SC, Renschler MF. Neurocognitive impairment in brain metastasis patients. *Neuro-Oncology* 1:326, 1999.
102. Mehta MP, Eisenberg P, Schultz CJ, Ford JM, Roa W, Leibenhaut M, Sze G, Einstein S, Renschler MF, Phan SC. Computer assisted masked MRI analysis of volumetric response: Implementation for a Phase III protocol of gadolinium texaphyrin (Gd-Tex) in patients with brain metastases. *Neuro-Oncology* 1:325, 1999.
103. Sanghavi SN, Mehta M: Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification. Proceedings of the 85<sup>th</sup> Scientific Assembly and Meeting of RSNA, Chicago IL, December, 1999.
104. Sanghavi S, Miranpuri S, Chappel R, Mabanta S, Regine W, Weltman E, Sneed P, Goetsch J, Breneman J, Sperduto P, Scott C, Buati J, Mehta M: Multi-institutional analysis of prognostic factors and survival outcome for radiosurgery treated patients with brain metastases, stratified by RTOG RPA classification. Proceedings of the LINAC Radiosurgery Annual Scientific Meeting, pg 37, Orlando, FL, December 1999
105. Mehta MP, Sanghavi SN, Miranpuri, SS, Chappell, R, Mabanta SR, Suh JH, Regine WF, Weltman E, Sneed PK, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Buatti JM: A Multi-Center database analysis predicting survival benefit for brain metastases patients treated with radiosurgery. *Cancer J*, 6:408, 2000.
106. Grossman SA, O'Neil A, Grunnet M, Mehta M, Pearlman J, Wagner H, Gilbert M, Newton H, Hellman R: Phase III study comparing three cycles of infusional BCNU/Cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2394-SWOG 9503). Proceedings of the American Society of Clinical Oncology, 19:158a, 2000.
107. Robins HI, Prados MD, Rao DR, Chang S, Yung A, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn J, Mehta MP. A Phase II trial of thymidine and carboplatin for

- recurrent malignant gliom: A North American Brain Tumor Consortium (NABTC) study. Proceedings of the American Society of Clinical Oncology 19:166a, 2000.
108. Schulz C, Mehta M, Robins HI, Badie B, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Wilding G, Kinsella T, et. al.: Continuous 28-day iododeoxyuridine (IudR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A Phase I Trial. Proceedings of the American Society of Clinical Oncology 19:194a, 2000.
  109. Shaw E, Scott C, Stea B, Suh J, Kadish S, Hackman J, Pearlman A, Gerber M, Murray K, Gaspar L, Mehta M, Curran W: Survival improvement with RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison to the radiation therapy oncology group recursive partitioning analysis brain metastases database. Proceedings of the American Society of Clinical Oncology, 19:159a, 2000.
  110. Merchant J, Hammes L, Brophy D, Larson M, Ripple G, Mehta M, Kim K, Schiller JH: Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology 19:541a, 2000.
  111. Mehta M, Meyers C, Schultz C, Ford J, Roa W, Leibenhaut M, Eber D, Phan S, Renschler M: Neurocognitive function (NF) predicts outcome in patients with brain metastases (BM) treated with whole brain radiation (WBRT) and Xyctrin. Proceedings of the American Society of Clinical Oncology 19:164a, 2000.
  112. Mehta MP, Meyers CA, Curran WJ, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Cmelak AJ, Rao A, Timmerman RD, Gaspar L, Phan SC, Eber D, Renschler MF: Xcytrin™ (Motexafin Gadolinium) and Whole Brain Radiation for Patients with Brain Metastases: Lead-In Phase to Randomized Trial – Final Results. Int J Radiat Oncol Biol Phys 48:204, 2000.
  113. Shaw E, Scott C, Stea B, Suh J, Kadish S, Hackman J, Pearlman A, Gerber M, Murray K, Gaspar L, Mehta M, Curran W: RSR13 plus cranial radiation therapy improves survival in patients with brain metastases compared to the RTOG recursive partitioning analysis brain metastases database: Update of a Phase II trial. Int J Radiat Oncol Biol Phys 48:203, 2000.
  114. Allen J, Prados M, Donahue B, Mehta M, Robertson P, Jakacki R, Sposto R: Phase I/II Study for Newly Diagnosed High Risk PNET Consisting of Neoadjuvant Chemotherapy (CHT) Followed by Hyperfractionated Radiotherapy (RT) – Preliminary Results of CCG Protocol 9931. Neuro-Oncology 2(4):247, October 2000.
  115. Prados MD, Yung WKA, Fine H, Greenberg H, Junk L, Chang S, Nicholas MK, Robins HI, Mehta MP, Fink K, Schiff D, Jaeckle KA, Kuhn J, Hess K, Schold C: A Phase II Study of BCNU and Temozolomide for Recurrent Glioblastoma Multiforme: A North American Brain Tumor Consortium Study. Neuro-Oncology 2(4):287, October 2000.

116. Scrimger RA, Mehta MP, Chappell RC, Tome WA: Spetzler grade and minimum dose are the most important prognostic factors in AVMs treated with stereotactic radiosurgery. Proceedings of the LINAC Radiosurgery Annual Scientific Meeting, pg 74-75, December 2000.
117. Forrest LJ, Vail DM, Smilowitz JB, Mackie TR, Olivera GH, Reckwerdt P, Mehta MP. Helical Tomotherapy. *Vet Radiol Ultrasound* 2000;41:573.
118. Mehta MP, Larson M, Schiller J: Phase I Trial of Gemcitabine as a Radiosensitizer for Non-Small Cell Lung Cancer. 5<sup>th</sup> Annual US Gemzar Investigators Meeting, Orlando, FL, March 2001.
119. M Mehta, M Ames, J Reid, G Vezina, J Kuttlesch, D LaFond, I Pollack, G Reaman, D Shaw, R Timmerman, M Krailo: Phase I study of Motexafin-Gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): A Children's Oncology Group study. Proceedings of the American Society of Clinical Oncology 20: 62a(# 243), 2001.
120. Forouzannia A, Mehta MP, Schiller JH, Hutson PR, Alberti DB, Feierabend CA, Kehrli NJ, Binger KA, Howard S, Pomplun ML, Wahamaki AS, McFarland T, Arzoomanian RZ, and Wilding G: Phase I Study Of Topotecan and Thoracic Radiation. Proceedings of the American Society of Clinical Oncology 20: 269b(# 2826), 2001.
121. Scott C, Seiferheld W, Prados M, Mehta M, Curran W: Is time to tumor progression (TTP) an appropriate endpoint for clinical trials in anaplastic astrocytomas (AA)? Analysis of Radiation Therapy Oncology Group (RTOG) study 9404. Proceedings of the American Society of Clinical Oncology 20: 51a(#200), 2001.
122. Sze G, Mehta M, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Cmelak AJ, Rao A, Timmerman RD, Gaspar L, Curran WJ, Phan SC, DeVault A, Renschler MF: Radiologic Response Evaluation Of Brain Metastases: Uni-Dimensional (1d) W.H.O. Recist Vs. Bi-Dimensional (2d) Or 3-Dimensional (3d) Criteria. Proceedings of the American Society of Clinical Oncology 20: 59a(# 234), 2001.
123. Mehta MP: Activities of the RTOG Brain Tumor Committee, 1996-2001. *Neuro-Oncol* 3:S26 (abstract 108), 2001.
124. Shaw E, Scott C, Stea B, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M: Phase II study of RSR13 + cranial radiation therapy in patients with brain metastases. *Neuro-Oncol* 3:S40 (abstract 166), 2001.
125. Miller RA, Renschler MF, Phan SC, Mehta MP: Motexafin Gadolinium: A tumor selective radiation enhancer for treatment of brain metastases. *Radiation Research* P26-349, 165, 2001.
126. Mehta MP: Lung Cancer: Dose Escalation Matters. Proceedings of the Sixth International Conference on Time Dose and Fractionation, pg 43-45, 2001.
127. Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz CJ, Timmerman R, Illidge T, Meyers CA, Curran WJ, Phan SC, Smith J, Renschler MF: Impairment of neurocognitive function in brain

- metastases patients: baseline results from the Phase III trial with Motexafin Gadolinium. *Int J Rad Oncol Biol Phys* 51:135 (abstract 242), 2001.
128. Forouzannia A, Mehta M, Sze G, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Cmelak AJ, Rao A, Timmerman RD, Gaspar L, Curran WJ, Phan SC, DeVault A, Renschler MF: A comparison of the radiologic response of brain metastases utilizing uni-dimensional (1D) W.H.O. recist, bi-dimensional (2D), and 3-dimensional (3D) criteria. *Int J Rad Oncol Biol Phys* 51:250 (abstract 2048), 2001.
  129. Rodrigus P, Mehta MP, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz CJ, Timmerman R, Illidge T, Curran WJ, Phan SC, Smith J, Renschler MF: Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with Motexafin Gadolinium. *Int J Rad Oncol Biol Phys* 51:410 (abstract 2349), 2001.
  130. De Stasio G, Frazer BH, Gilbert B, Schaub S, Mercanti D, Casalbore P, Larocca LM, Rinelli A, Mehta MP, Pallini R: Tumor-Specific Intracellular Delivery of Gadolinium for Glioblastoma. *Int J Rad Oncol Biol Phys* 51:251 (abstract 2050), 2001.
  131. Kapatoes JM, Olivera GH, Schloesser EA, Pearson DW, Balog JP, Ruchala KJ, Schmidt R, Reckwerdt P, Mehta MP, Mackie TR: Gating-by-Rotation: A Solution to the Problem of Intratreatment Motion in Helical Tomotherapy. *Int J Rad Oncol Biol Phys* 51:95 (abstract 169), 2001.
  132. Mehta MP, Seiferheld W, Delrowe J, MacDonald D, Langer C, Scott C, Curran W, Yung A: Glioblastoma Multiforme: The Phase II RTOG Experience. *Neuro-Oncol* 3:350 (abstract 332), 2001.
  133. Mehta M, Hayes L, Robins HI, Badie, B, Rao R: Acute Side Effects of Radiosurgery. *Neuro-Oncol* 3:351 (abstract 333), 2001.
  134. Chadha S, Salamat M Sh, Mehta M: Lack of Correlation between HER2/neu Expression, Histologic Parameters, and Cell Proliferation Indices in Oligodendrogliomas. *Neuro-Oncol* 3:326 (abstract 243), 2001.
  135. De Stasio G, Frazer BH, Gilbert B, Schaub S, Mercanti D, Casalbore P, Larocca LM, Rinelli A, Mehta MP, Pallini R: Tumor-Specific Intracellular Delivery of Gadolinium in Glioblastoma. *Neuro-Oncol* 3:348 (abstract 322), 2001.
  136. MP Mehta, P Rodrigus, C Terhaard, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, and MF Renschler. Impaired Neurocognitive Function (Ncf) In Brain Metastasis (Bm) Patients (Pts) Is Strongly Correlated With Worse Quality Of Life (Qol): Baseline Results From The Phase III Trial Of Motexafin Gadolinium (MGD). *Neuro-Oncol* 3:292-3 (abstract 292), 2001.
  137. Passe SM, Law ME, Cairncross JG, Curran WJ, Scott CB, Mehta M, Scheithauer BW, Jenkins RB: A Pilot Analysis of 1p and 19q Deletions in Anaplastic Oligodendrogliomas and Mixed Oligoastrocytomas from RTOG Trial 94-02. *Neuro-Oncol* 3:332 (abstract 263), 2001.



138. Cloughsey T, Kuhn J, Robins I, DeAngelis L, Chang S, Schiff D, Wen P, Yung A, Gilbert M, Fink K, Junck L, Abrey L, Lieberman F, Mehta M, Reizer J, Prados M: Phase I trial of R115777 in patients with recurrent malignant glioma taking enzyme inducing antiepileptic drugs (EIAED). North American Brain Tumor Consortium. Neuro-Oncol 3:357 (abstract 358), 2001.
139. Cloughsey T, Kuhn J, Wen P, Chang S, Schiff D, Greenberg H, Junck L, Robins I, DeAngelis L, Yung A, Fink K, Abrey L, Lieberman F, Mehta M, Reizer J, Hess K, Prados M: Phase II trial of R115777 in patients with recurrent malignant glioma not taking enzyme inducing antiepileptic drugs (EIAED). North American Brain Tumor Consortium. Neuro-Oncol 3:357 (abstract 359), 2001.
140. Heiner J, Mehta M, Bailey H, Fowler J, Kinsella T, Lamson M, Storm FK: Neoadjuvant adriamycin and twice daily radiotherapy in adult soft tissue sarcoma. Proceedings of the Connective Tissue Oncology Society (abstract 22), 2001.
141. W Seiferheld, MP Mehta, J Delrowe, D MacDonald, C Langer, C Scott, W Curran, A Yung: Five Years of Glioblastoma Multiforme (GBM) Phase II Trials at the Radiation Therapy Oncology Group (RTOG). Proceedings of the American Society of Clinical Oncology 21: 71a(# 281), 2002.
142. Wagner LI, Rue M, Fisch M, Cleeland C, Bonomi PD, Schiller JH, Mehta MP, Petereit D, DeVore RF, Johnson DH, Cella D. Neuropsychiatric Symptoms During Cancer Treatment: An Examination of Quality of Life Data from Two ECOG Lung Cancer Trials. Proceedings of the American Society of Clinical Oncology 21: 357a(#1426), 2002.
143. Cloughesey T, Kuhn J, Wen P, Chang S, Schiff D, Greenberg H, Junck L, RobinsI, DeAngelis LM, Yung A, Fink K, Abrey L, Lieberman F, Mehta M, Reizer J, Hess K and Prados M. Phase II Trial of R115777 in Patients with Recurrent Glioma not taking Enzyme Inducing Antiepileptic Drugs (EIAED). A Preliminary Report. North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology 21: 80a(#317), 2002.
144. PY Wen, WKA Yung, K Hess, S Silberman, M Hayes, D Schiff, F Lieberman, T Cloughesey, LM DeAngelis, S Chang, L Junck, H Fine, K Fink, I Robbins, J Raiser, L Abrey, M Mehta, E Maher, PM Black, R Capdeville, R Kaplan, A Murgo, C Stiles, MD Prados. Phase I Study of STI571 (Gleevec) For Patients With Recurrent Malignant Gliomas and Meningiomas (NABTC 99-08). Proceedings of the American Society of Clinical Oncology 21: 73a(#288), 2002.
145. Kuhn J, Prados M, Robins I, DeAngelis LM, Chang S. Schiff D, Wen P, Yung A, Gilbert M, Fink K, Greenberg H, Junck L, Abrey L, Lieberman F, Mehta M, Reizer J, Hess K, and Cloughesey T. Phase I Trial of R115777 (Zarnestra) in Patients with Recurrent Malignant Glioma taking Enzyme Inducing Antiepileptic Drugs (EIAED). A North American Brain Tumor Consortium (NABTC) Report. Proceedings of the American Society of Clinical Oncology 21: 86a(#342), 2002.
146. J Suh, E Chang, R Timmerman, J Yamada, L Gaspar, M Leibenhaut, A Rao, S Phan, WK A Yung, M Mehta. Phase II Trial of Motexafin Gadolinium (MGd, Xcytrin<sup>R</sup>) and Cranial

Radiation in Newly Diagnosed Glioblastoma Multiforme. Proceedings of the American Society of Clinical Oncology 21: 74b(#2108), 2002.

147. P Rodrigus, MP Mehta, C Terhaard, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, and MF Renschler. Impaired Neurocognitive Function in Brain Metastasis Patients is Strongly Correlated with MRI Tumor Volume and Tumor Histology: Baseline Results from the Phase III Trial of Motexafin Gadolinium. Proceedings of the American Society of Clinical Oncology 21: 74a(# 292), 2002.
148. DR Miles, JM Ford, MP Mehta, C Schultz, P de Brouwer, H Dehnad, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, SJ Hutcheson, G Boswell, S Phan, and M Renschler. An evaluation of gender, alkaline phosphatase, and cytochrome P450 on Motexafin Gadolinium pharmacokinetics in Patients with brain tumors using a population pharmacokinetic analysis. Proceedings of the American Society of Clinical Oncology 21: 119a(#474), 2002.
149. C Terhaard, MP Mehta, P Rodrigus, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, and MF Renschler. Quality of Life (QOL) in Patients (Pts) with Brain Metastases (BM) is Strongly Related to MRI Tumor Volume and Neurocognitive Function (NCF): Baseline Results from the Phase III Trial of Motexafin Gadolinium (MGd). Proceedings of the American Society of Clinical Oncology 21: 73a(# 290), 2002.
150. MP Mehta, P Rodrigus, C Terhaard, A Rao, J Suh, W Roa, WR Shapiro, MJ Glantz, RA Patchell, MA Weitzner, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W Curran, S Phan, J Smith, RA Miller, and MF Renschler. Results from the Phase III Trial of Motexafin Gadolinium (MGd) in Brain Metastases. Proceedings of the American Society of Clinical Oncology 21: 72a(# 286), 2002.
151. L Souhami, C Scott, D Brachman, E Podgorsak, M Werner-Wasik, R Lustig, CJ Schultz, W Sause, P Okunieff, J Buckner, L Zamorano, M Mehta, W Curran. Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): Report of RTOG 93-05 protocol. ASTRO 2002 (submitted).
152. W. F. Regine, F. A. Schmitt, C. Scott, C. Dearth, R. A. Patchell, R. C. Nichols, Jr. E. Gore, R.L. Franklin III, J. Suh, M. Mehta. Feasibility of Neurocognitive Evaluations in Patients with Brain Metastases in a Multi-Institutional Cooperative Group Setting: Results of Radiation Therapy Oncology Group (RTOG) Trial BR-0018. ASTRO 2002 (submitted).
153. L.J. Forrest, T.R. Mackie, K.J. Ruchala, M.P. Mehta. Megavoltage CT Images from a Helical Tomotherapy System. ASTRO 2002 (submitted).
154. R Manon, P Chinnaiyan, S Hui, S Phan, J Suh, E Chang, R Timmerman, S Phan, R Das, M Mehta. The Impact of a Mid-Treatment MRI on Defining GBM Boost Volumes. ASTRO 2002 (submitted).

155. W. Seiferheld, A. Chakravarti, K. Ang, E. Hammond, W. Curran, M. Mehta. Overexpression of the Epidermal Growth Factor Receptor (EGFR), as Determined by EGFR Immunostaining on Tissue Microarrays, fails to Demonstrate Independent Prognostic Value for Patients with Glioblastoma Multiforme: A Report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602, and 9806. ASTRO 2002 (submitted).
156. W. Curran, M P Mehta, C Terhaard, A Rao, J Suh, W Roa, WR Shapiro, M J Glantz, RA Patchell, MA Weitzner, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W J Curran, S Phan, J Smith, A DeVault, R Miller, M F Renschler. Predictors of Survival for Patients with Brain Metastases: Results of a Randomized Phase III Trial. ASTRO 2002 (submitted).
157. M P Mehta, P Rodrigus, C Terhaard, A Rao, J Suh, W Roa, WR Shapiro, M J Glantz, RA Patchell, MA Weitzner, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W J Curran, S Phan, J Smith, A DeVault, R Miller, M F Renschler. Motexafin Gadolinium Prolongs Time to Neurologic Progression in Lung Cancer Patients with Brain Metastases: Results of a Randomized Phase III Trial. ASTRO 2002 (submitted).
158. T.R. Mackie, GH Olivera, PJ Reckwerdt, S Becker, W Tomé, M Ritter, M.P. Mehta. Helical Tomotherapy for the Treatment of Simple Radiotherapy Cases. ASTRO 2002 (submitted).
159. W A. Tomé, H A. Jaradat, T R. McNutt, M. E Meyerand, Mehta MP. Application of multimodality imaging to radiation therapy treatment planning of brain tumors. ASTRO 2002 (submitted).
160. M Renschler, M P Mehta, P Rodrigus C Terhaard, A Rao, J Suh, W Roa, L Souhami, A Bezjak, M Leibenhaut, R Komaki, C Schultz, R Timmerman, T Illidge, C Meyers, W J Curran, A DeVault, R Miller, S Phan. Smokers with Brain Metastases Have a More Aggressive Disease and Worse Outcome than Non-Smokers. ASTRO 2002 (submitted).
161. Bradley K, Hong T, Hayes L, Tomé W, Reznick D, Mehta M. LINAC Radiosurgery for Trigeminal Neuralgia. ASTRO 2002 (submitted).
162. G De Stasio, BH Frazer, B Gilbert, D Mercanti, P Casalbore, LM Larocca, A Rinelli, R Pallini, D. Rajesh, SP Howard, JF Fowler and MP Mehta. Reevaluating GdNCT intranuclear delivery of Gd in glioblastoma cells and tissues. NCT Conference, Essen, Germany, Sep. 2002 (submitted).
163. A Forouzannia, G Olivera, J Kapatoes, W Lu, J Fowler, J Welsh, TR Mackie, M Mehta. Stereoblation Of Early Stage Lung Tumors Using Helical Tomotherapy. ASTRO 2002 (submitted).
164. L.J. Forrest, T.R. Mackie, K.J. Ruchala, M.P. Mehta: Helical Tomotherapy: Megavoltage CT Images for Set-up Verification. RSNA 2002 (submitted).

**PUBLICATIONS–BOOK CHAPTERS/MONOGRAPHS:**

1. Mehta MP: Special applications of radiation therapy. In: Current Therapy in Hematology Oncology, Brain and Carbone (eds), 4th edition, B.C. Decker, Philadelphia, Pennsylvania, pp 464-468, 1991.
2. Mehta MP, Turski PA, Petereit DG, Strother CM, Levin AB, Kinsella TJ: Assessment of arteriovenous malformations pre and post stereotactic radiosurgery using magnetic resonance angiography. In: Stereotactic Radiosurgery Update, Lunsford L.D. (ed), Elsevier Press, New York, New York, pp 129-138, 1992 .
3. Mehta MP, Anderla D, Gehring MA, Mackie TR, Kinsella TJ: Dose optimization for stereotactic radiosurgery. In: Stereotactic Radiosurgery Update, Lunsford L.D. (ed), Elsevier Press, New York, New York, pp 229-234, 1992 .
4. Levin AB, Mehta MP, Mackie TR, Rozental JM, Kubsad SS: Stereotaxic focused radiation in metastatic lesions to the brain. In: Stereotactic Radiosurgery Update, Lunsford L.D. (ed), Elsevier Press, New York, New York, pp 445-451, 1992 .
5. Mehta MP: Radiosurgery for brain metastases. In: Stereotactic Surgery and Radiosurgery, DeSalles AF, Goetsch SJ (eds), Medical Physics Publishing Corporation, Madison, Wisconsin, pp 353-368, 1993.
6. Mehta MP, Speiser BL, Macha H: High dose-rate brachytherapy for lung cancer. In: Textbook on High Dose-Rate Brachytherapy, Nag (ed), Futura Publishing Company, Mount Kisco, New York, pp 295-319, 1994.
7. Mehta MP: Role of brachytherapy-the American experience. In: Minimally Invasive Techniques in Thoracic Medicine and Surgery, Hetzel (ed), Chapman and Hall Medical, London, UK, pp 205-216, 1995.
8. Mehta MP, Rozental JM: Radiotherapy of pituitary hypothalamic tumors. In: Principles and Practice of Endocrinology and Metabolism, 2nd edition, Becker (ed), J.B. Lippincott Publishing Company, Philadelphia, Pennsylvania, pp 229-237, 1995.
9. Behal R, Cummings BJ, Ratko T, Bova FJ, Friedman W, Larson, D, Lunsford, LD, Matuszewski K, Mehta MP: Technology Report: Stereotactic radiosurgery. University Hospital Consortium Clinical Practice Advancement Center, Oakbrook, Illinois, 1995.
10. Mehta MP, Kinsella TJ: Superior vena cava syndrome. In: Thoracic Oncology, Roth, Ruckdeschel and Weisenburger (eds), W.B. Saunders Company, pp 239-258, 1995.
11. Noyes WR, Auchter RM, Craig B, French MC, Johnson MN, Lamond JP, Levin AB, Kinsella TJ, Mehta MP: Cost analysis of radiosurgery versus resection for single brain metastases. In: Radiosurgery 1995, Kondziolka D (ed), S. Karger Publishers, Basel, Switzerland, pp 172-179, 1996.
12. Mehta MP: Endobronchial radiation therapy. In: Lung Cancer, Pass, Mitchell, Johnson and Turrissi (eds), J.B. Lippincott Publishing Company, pp 741-750, 1996.

13. Mehta MP: Radiosurgery: Primary and metastatic malignant brain tumors. In: Minimally Invasive Therapy of the Brain, De Salles AF, Lufkin R (eds), Thieme Medical Publishers, pp 213-224, 1996.
14. Mehta MP, Noyes WR: Solitary brain metastases. In: Tumor Board Case Management, Winchester DP, et al (eds), Lippincott-Raven Publishing Company, Philadelphia, PA, pp 640-648, 1996.
15. Mehta MP, Sneed PK: Interstitial radiation therapy for brain tumors. In: Principles and Practice of Brachytherapy, Nag S (ed), Futura Publishing Company, Mount Kisco, New York, pp 247-268, 1997.
16. Mehta MP, Lamond J, Nori D, Speiser B: Brachytherapy of lung cancer. In: Principles and Practice of Brachytherapy, Nag S (ed), Futura Publishing Company, Mount Kisco, New York, pp 323-350, 1997.
17. Mehta MP: Role of chemotherapy and radiation therapy in the treatment of locally advanced non-small cell lung cancer. In: Updates on Advances in Lung Cancer, Schiller JB (ed), S. Karger Publishers, Basel, Switzerland, pp. 35-55, 1997.
18. Boyd T, Mehta MP: A comprehensive review of the role of radiosurgery in patients with intracranial metastases. In: Radiosurgery 1997, Kondziolka D (ed), S. Karger Publishers, Basel, Switzerland, pp. 31-50, 1998.
19. Mehta MP, Boyd T, Loeffler J: Linear accelerator stereotactic radiosurgery using single and fractionated treatment schemes for cerebral metastases. In: Advanced Techniques in Central Nervous System Metastases, Maciunas RJ (ed), AANS, pp 135-154, 1998.
20. Mehta MP: Radiation Pneumonitis: The Clinical Syndrome, Pathophysiology, and Molecular Basis. In: Volume & Kinetics In Tumor Control and Normal Tissue Complications; Paliwal, Fowler, Herbert, Mehta (eds), Medical Physics Publishing, pp 264-276, 1998.
21. Paliwal BR, Fowler JF, Herbert DE, Mehta MP (editors): Volume and Kinetics In Tumor Control and Normal Tissue Complications; Medical Physics Publishing, 1998.
22. Mehta MP, Kinsella TJ: Superior vena cava syndrome: Clinical features, diagnosis and treatment. In: General Thoracic Surgery, Shields, LoCicero and Ponn (eds), Williams and Wilkins, pp 2149-2166, 2000.
23. Mehta MP, Harari PM: Altered Fractionation Schedules for Lung Cancer. In: Lung Cancer Principles and Practice, 2<sup>nd</sup> edition; Pass, Mitchell, Johnson, Turrisi, Minna (eds), Lippincott Williams & Wilkins, pp 843-852, 2000.
24. Mehta MP, Schiller JH: Diagnosis and Management of Stage III NSCLC. Clinical Oncology Update, 3(3)1-15, 2000.
25. Sahel J, Polans A, Mehta MP, Auchter R, Alberts D: Intraocular melanoma. In: Principles and Practice of Oncology, DeWita (ed), 6<sup>th</sup> edition, Lippincott-Raven, pp, 2070-2090, 2001.

26. Mehta MP: Radiotherapy of pituitary hypothalamic tumors. In: Principles and Practice of Endocrinology and Metabolism, 3rd edition, Becker (ed), J.B. Lippincott Publishing Company, Philadelphia, Pennsylvania, pp 243-254, 2001.
27. Schiller J, Mehta MP: Treatment options for Non Small Cell Lung Cancer: Abstract Review: Current Research and Expert Commentary, Education Editor, Medical Education Network, New York, New York, 2001.
28. Kesslering C, Mehta MP: Neural tumors. In: Management of Metastatic Disease to the Musculoskeletal System. Heiner JP, Kinsella TJ and Zdeblick TA (eds), Quality Medical Publishing, St. Louis, MO, pp 295-302, 2002.
29. Mehta M, Treont-Lukats I: Evaluation and Management of Brain Metastases. In: American Society of Clinical Oncology Educational Book. Perry MC (ed), ASCO, Alexandria, VA, pp 375-382, 2002.
30. Mehta MP, Kinsella TJ: Treatment of low grade intramedullary gliomas. In: Controversies in Spine Surgery, Zdeblick TA, Benzel EC, Anderson P, Stillerman CB (eds), 2002 (in press).
31. Mehta MP: Fractionated Radiation Therapy for Malignant Brain Tumors. In: Youman's Neurological Surgery (Chapter 9.4.1), H. Richard Winn MD (ed), W. B. Saunders Company, 2002 (in press).
32. Mehta MP, Tremont I: Radiosurgery for Single and Multiple Metastasis. In: Intracranial Metastases: Current Management Strategies, Sawaya R (ed), Futura Publishing, pp., 2002 (in press).
33. Mehta MP, Tremont I: Brain Metastases. In: Clinical Practice of Hematology and Oncology: Presentation, Diagnosis and Treatment, Furie B, Mayer RJ, Cassileth P, Atkins M (eds), Harcourt Inc, pp., 2002 (in press).
34. Gilbert M, Tome W, Mehta MP: Neuro-oncology. In: Atlas of Cancer, Markman M (ed), Current Medicine, Philadelphia, PA, pp., 2002 (in press).
35. Mehta MP, Bradley K: Radiation Therapy for Leptomeningeal Cancer. In: Leptomeningeal Cancer, Engelhard HH, Chamberlain M (eds), Kluwer Academic Publishers, Norwell, MA, pp., 2002 (in press).
36. Mehta MP, Patel R: Radiosurgery for Brain Metastases. In: \_\_\_\_\_, Loeffler J, \_\_\_\_\_ (eds), \_\_\_\_\_, pp., 2002 (in press).

#### INVITED PRESENTATIONS:

1. Childhood meningitis: State-of-the-art, 1981. Arthur Davison Children's Hospital Pediatric Grand Rounds, Ndola, Zambia, 1981.

2. Detailed analysis of the incidence, clinical features, management and complications of gunshot injuries in Ndola, Zambia, 1979-81. Surgical Grand Rounds, Ndola Central Hospital, Ndola, Zambia, 1981.
3. Hemobilia: Presentation and management. Surgical Grand Rounds, Ndola Central Hospital, Ndola, Zambia, 1981.
4. Traumatic diaphragmatic herniation. Surgical Grand Rounds, Ndola Central Hospital, Ndola, Zambia, 1981.
5. "Radioimmunotherapy, the magic bullet". Wisconsin Society of Radiation Oncology, Oconomowoc, WI, February 1987.
6. Report of a pilot study of endobronchial irradiation. Wisconsin Society of Radiation Oncologists, Oconomowoc, WI, February 1988.
7. Endobronchial irradiation for malignant airway obstruction. Human Oncology Grand Rounds, UWCCC, Madison, WI, April 1988.
8. An *in vivo* model for dosimetric analysis of radiolabeled monoclonal antibodies. American Association for Cancer Research, New Orleans, LA, May 1988.
9. Non-small cell lung cancer: Radiotherapeutic perspectives. Human Oncology Grand Rounds, UWCCC, Madison, WI, August 1988.
10. Time dose fractionation overview. Third International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison, WI, September 1988.
11. Radiation osteolysis. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison, WI, September 1988.
12. Endobronchial brachytherapy for malignant airway obstruction. 30th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, New Orleans, LA, October 1988.
13. Stereotactic radiotherapy for arteriovenous malformations. Radiology Grand Rounds, University of Wisconsin Hospital & Clinics, Madison, WI, January 1989.
14. Radiotherapy in the management of lung and esophageal malignancies. Thoracic Surgery Grand Rounds, University of Wisconsin Hospital & Clinics, Madison, WI, March 1989.
15. Non-small cell lung cancer: Overview and focus on brachytherapy. 4th Annual Comprehensive Management of Chronic Respiratory Problems, Madison, WI, March 1989.
16. Endobronchial radiation therapy for malignant airway obstruction. Annual Meeting of the Wisconsin Thoracic Society, Milwaukee, WI, March 1989.

17. The curative potential of radiation therapy in the management of non-small cell lung cancer. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison, WI, March 1989.
18. Radiotherapy applications and developments. University of Iowa/Mercy Hospital Cancer Conference, Davenport, IA, June 1989.
19. CT based dose-volume analysis of small bowel during pelvic external radiation therapy. Kubsad SS, Mehta MP, Gehring MA, Shanahan TG, Paliwal BR, Kinsella TJ. 31st Annual Meeting of the American Association of Physicists in Medicine, , Memphis, TN, July 23-27 1989.
20. Radioimmunotherapy: Dosimetric and biological analysis. 31st Annual Meeting of the American Society of Therapeutic Radiology and Oncology, San Francisco, CA, October 1989.
21. Innovative radiotherapy: Stereotaxic radiotherapy. Fall Meeting of the Radiation Therapy Technologists of Wisconsin, Madison, WI, October 1989.
22. Stereotaxic radiotherapy: Initial experience using a linear accelerator. Notre Dame, IN, February 1990.
23. Radiotherapeutic innovations in the management of non-small cell lung cancer. University of Wisconsin Regional Lung Cancer Conference, Madison, WI, March 1990.
24. The evolving role of radiotherapy in the management of small cell carcinoma of the lung. University of Wisconsin Regional Lung Cancer Conference, Madison, WI, March 1990.
25. Stereotactic radiosurgery for brain metastases. University of Wisconsin, Medical Physics Seminar, Madison, WI, April 1990.
26. Stereotactic radiosurgery for brain metastases, the early experience. University of Wisconsin Colloquium in Human Cancer Biology, Madison, WI, May 1990.
27. Brain tumor response following stereotactic radiotherapy. 26th Annual Meeting of the American Society for Clinical Oncology, Washington, DC, May 1990.
28. Brain neoplasms: Current limitations and future prospects. Wausau Regional Cancer Center, Wausau, WI, May 1990.
29. Stereotactic radiation: Evaluation of early brain tumor response. Harvard Radiosurgery Update, Chestnut Hill, MA, June 1990.
30. The role of stereotactic radiosurgery in the management of pituitary tumors. University of Wisconsin Endocrine Grand Rounds, Madison, WI, August 1990.
31. A review of stereotactic radiosurgery for brain metastases. 3rd Midwest Neuro-Oncology Conference, Madison, WI, August 1990.



32. Stereotactic radiation: Evaluation of early brain tumor response. 32nd Annual American Society of Therapeutic Radiology Oncology Meeting, Miami Beach, FL, October 1990.
33. Hyperfractionated high dose rate endobronchial irradiation. 13th Annual American Endocurietherapy Society Meeting, San Diego, CA, December 1990.
34. Urgent management of high airway obstruction. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison, WI, January 1991.
35. Treatment of brain metastasis with stereotactic radiation. Levin AB, Mehta MP, Mackie TR. Linde Winter Neurosurgical Meeting, Snowbird, UT, February 1991.
36. Medical issues in stereotactic radiosurgery. Workshop on Stereotactic External Beam Radiation Therapy, University of Wisconsin, Madison, WI, February 1991.
37. High dose rate endobronchial radiation: technical and clinical parameters. Petereit DG, Mehta MP, Fowler JF, Shahabi S, Thomadsen BR, Kinsella TJ. Wisconsin Society of Radiation Oncology, Oconomowoc, WI, February 1991.
38. Management of CNS Neoplasms with stereotactic radiosurgery. Human Oncology Grand Rounds, UWCCC, Madison, WI, March 1991.
39. Stereotactic focussed radiation in metastatic lesions to the brain. Levin AB, Mehta MP, Rozenal JM, Mackie TR, Kubsad SS. American Association of Neurological Sciences Meeting, New Orleans, LA, April 1991.
40. The management of pelvic recurrence of rectal cancer: Radiotherapeutic intervention for pelvic recurrence: preoperative, intraoperative and postoperative. 26th Annual Cincinnati Cancer Symposium, Cincinnati, OH, April 1991.
41. Assessment of arteriovenous malformations pre and post stereotactic radiosurgery using magnetic resonance angiography. International Stereotactic Radiosurgery Symposium, Pittsburgh PA, June 1991.
42. Dose optimization for stereotactic radiosurgery. International Stereotactic Radiosurgery Symposium, Pittsburgh, PA, June 1991.
43. A stereotactic radiosurgery treatment planning and simulation system. Gehring MA, Mackie TR, Mehta MP, Sanders CL, Reckwerdt PJ, Kubsad SS, Kinsella TJ. International Stereotactic Radiosurgery Symposium, Pittsburgh, PA, June 1991.
44. Identification of an optimal subgroup of patients with brain metastases suitable for stereotactic radiation. Levin AB, Mehta MP, Mackie TR, Rozenal J, Kubsad SS. International Stereotactic Radiosurgery Symposium, Pittsburgh, PA, June 1991.
45. Strategies to enhance radiosurgical responses. 9th International Conference on Brain Tumor Research and Therapy, Pacific Grove, CA, October 1991.

46. Acute changes in brain tumor metabolism after treatment with stereotactic radiotherapy. Rozental JM, Mehta MP, Levine RL, Kinsella TJ, Levin AB. 9th International Conference on Brain Tumor Research and Therapy, Pacific Grove, CA, October 1991.
47. Radiosurgery for brain metastases. 33rd Annual American Society of Therapeutic Radiology Oncology Meeting, Washington, DC, October 1991.
48. Stereotactic radiation therapy at the University of Wisconsin. Tufts University, Boston, MA, January 1992.
49. Stereotactic irradiation for high grade gliomas. Bastin K, Mehta MP, Levin AB, Kinsella TJ. Wisconsin Society of Radiation Oncology, Oconomowoc, WI, February 1992.
50. Radiation therapy of lung cancer. Pulmonary Conference University of Wisconsin, Madison, WI, March 1992.
51. New approaches to radiation therapy. Freeport Memorial CME Program, Freeport IL, March 1992.
52. Special procedures in radiation therapy. State Medical Society Annual Meeting, Milwaukee WI, April 1992.
53.  $^1\text{H}$  MR spectroscopy of human brain tumors *in vivo* using optimized RF pulses. Thomas AM, Rodriguez R, Ryner L, Mehta MP, Brown P, Rozental JM, Turski PA. 11th Annual Meeting of Society of Magnetic Resonance in Medicine, Berlin, Germany, August 1992.
54. Evaluation of cerrobend block weight. Paliwal BR, Rieger J, Mehta MP, Kubsad SS. 34th Annual Meeting of American Assn of Physicists in Medicine, Calgary, Alberta, Canada, August 1992.
55. Radiosurgery for arteriovenous malformations based on magnetic resonance angiography. Kubsad SS, Mehta MP, Petereit DP, Turski PA: International Conference on Medical Physics and Radiation Safety, Bombay, India, September 1992.
56. Stereotactic radiosurgery using a linear accelerator. Kubsad SS, Mackie TR, Gehring MA, Mehta MP, Paliwal BR, Kinsella TJ. International Conference on Medical Physics and Radiation Safety, Bombay, India, September 1992.
57. Lung cancer. 38th Annual Fall Cancer Conference, Madison, WI, September 1992.
58. Brachytherapy in lung cancer. ECOG, Spring Meeting, Atlanta, Georgia, February 1993.
59. Treatment of malignant glioma with stereotactic radiosurgery. Levin AB, Mehta MP, Masciopinto JE, Rohde B. Linde Winter Neurosurgical Meeting, Snowbird, UT, February 1993.
60. Preliminary analysis of multivoxel  $^1\text{H}$  MR spectroscopic imaging for CNS neoplasms. 41st Annual Meeting of Radiation Research Society, Dallas, TX, March 1993.

61. Colony Stimulating Factors: From Laboratory to Clinical Applications. St. Luke's Medical Center Symposium, Milwaukee, WI, April 1993.
62. Update on radiation oncology for lung cancer. Lung Cancer Seminar, St. Vincent's Hospital, Green Bay WI, April 1993.
63. Surgery vs. radiosurgery for brain metastases. 1st Congress of the International Stereotactic Radiosurgery Society, Stockholm, Sweden, June 1993.
64. Recent advances in radiation oncology. Clinical Oncology Seminar, Wisconsin Rapids WI, June 1993.
65. Compensation of opposing lung fields with a 3-D dose compensation system. Wendt R, Brock L, Haney P, Paliwal BR, Jursinic P, Mehta MP, Kinsella TJ. 18th Annual Meeting of American Association of Medical Dosimetrists, Atlanta, Georgia, June 1993.
66. Management of brain metastases with stereotactic radiosurgery: "Hands-On" Stereotactic Surgery and Radiosurgery Workshop. Los Angeles, CA, August 1993.
67. A review of endobronchial HDR brachytherapy. 7th Annual Brachytherapy Symposium, Columbus, OH, September 1993.
68. Clinical Neuro-Oncology: UW Experience. Wisconsin Radiological Society/Wisconsin Radiation Oncology Society. 1993 Fall Scientific Program, Madison, WI, October 1993.
69. Glioblastoma treated with external beam radiotherapy and stereotactic radiosurgery boost. 35th Annual Meeting of American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1993.
70. Compensation of opposing lung fields with a 3-D dose compensation system. Wendt R, Brock L, Haney P, Paliwal B, Jursinic P, Mehta MP, Kinsella TJ. 35th Annual Meeting of American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1993.
71. Five-year experience with linear-accelerator based stereotactic radiosurgery. ADAC Users' Group Meeting at the 35th Annual Meeting of American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1993.
72. Stereotactic radiosurgery for glioblastoma: An update. Levin AB, Masciopinto JE, Mehta MP. The Congress of Neurologic Surgeons. Vancouver, Canada, October 1993.
73. Stereotactic radiosurgery for glioblastoma multiforme. Levin AB, Masciopinto JE, Mehta MP. The World Society for Stereotactic and Functional Neurosurgery, Ixtapa, Mexico, October 1993.
74. Preliminary analysis of CO 9052, a Phase II study of Cisplatin, Vinblastine and WR 2721 with external beam radiotherapy and WR 2721 for advanced, unresectable, non-metastatic non-small cell lung cancer. U.S. BioSciences Annual Meeting, Philadelphia, PA, November 1993.

75. Combined modality management of cancer of the esophagus. Surgical Grand Rounds, University of Wisconsin, Madison WI, October 1993.
76. Acute morbidity of the upper aerodigestive tract during radiotherapy. Annual Conference of the Wisconsin Dietetic Association, Madison WI, November 1993.
77. Stereotactic radiosurgery: Clinical, biological and technical ramifications. Cleveland Clinic, Cleveland OH, November 1993.
78. Current status of stereotactic radiosurgery. Neurosurgical Grand Rounds, University of Wisconsin, Madison WI, January 1994.
79. Future strategies to improve outcome in childhood malignant gliomas. CCG Glioma Working Group, Philadelphia PA, January 1994.
80. Radiosurgery applications: Metastatic brain lesions: Fourth Annual Course on Minimally Invasive Therapy of the Brain, Santa Monica CA, August 1994.
81. Radiosurgery limitations: Response of vascular and nervous tissue to radiosurgery: Fourth Annual Course on Minimally Invasive Therapy of the Brain, Santa Monica CA, August 1994.
82. Can we justify randomized studies using radiosurgery for patients with metastatic disease and, if so, what should be done? The Preuss Foundation seminar on Stereotactic Radiation Treatment of Brain Tumors, Boston MA, September 1994.
83. What are the costs of radiosurgery and can society afford these costs? The Preuss Foundation seminar on stereotactic radiation treatment of brain tumors, Boston MA, September 1994.
84. Cost comparison of radiosurgery and surgery for the treatment of brain metastases. 36th Annual Meeting of American Society for Therapeutic Radiology and Oncology, San Francisco CA, October 1994.
85. Current issues in stereotactic radiosurgery for brain tumors. Current status of radiosurgery in the United States for malignant and benign tumors. Loyola University Medical Center, Chicago IL, November 1994.
86. Second neoplasms after successful therapy for initial malignancy in childhood. Combined Hospitals Tissue Conference, William S. Middleton Veterans' Memorial Hospital, Madison WI, November 1994.
87. Radiosurgery versus Brachytherapy for malignant glioma. 17th Annual Mid-Winter Meeting of the American Brachytherapy Society, Sanibel Island FL, December 1994.
88. Cost comparison of stereotactic radiosurgery versus surgical resection for brain metastases. Noyes WR, Mehta MP. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1995.

89. The potential promise of radiosurgery. Eastern Cooperative Oncology Group, Denver CO, April 1995.
90. Imaging techniques for radiosurgery: Pre- and post-radiosurgery. The 2nd Congress of the International Stereotactic Radiosurgery Society, Boston MA, June 1995.
91. New strategies for malignant glioma management. Beloit Hospital Tumor Board, Beloit WI, June 1995.
92. An overview of the current status of outcomes measures in therapeutic radiology. 37th Annual Meeting of the American Association of Physicists in Medicine, Boston MA, July 1995.
93. Management of acute neuro-oncologic conditions. Neurology Grand Rounds, University of Wisconsin, Madison WI, August 1995.
94. Radiosurgery for metastatic brain tumors. UCLA Fifth Annual Workshop on Minimally Invasive Therapy of the Brain, Santa Monica CA, September 1995.
95. Malignant brain tumors; the role of radiosurgery. Gamma Knife Workshop on Stereotactic Radiosurgery, San Diego CA, October 1995.
96. Technology report: Stereotactic radiosurgery. University Hospital Consortium and the Clinical Practice Advancement Center, Miami FL, October 1995.
97. An overview of radiosurgery. 37th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Miami FL, October 1995.
98. Brain cancer. St. Francis Medical Center Grand Rounds, La Crosse WI, October 30, 1995.
99. Human experience with meningioma. University of Wisconsin, School of Veterinary Medicine Grand Rounds, Madison WI, December 1, 1995.
100. Metastases: Conventional radiation and radiosurgery. LINAC Radiosurgery 1995, University of Florida, Orlando FL, December 1995.
101. Radiosurgery versus surgery: A cost benefit analysis. LINAC Radiosurgery 1995, University of Florida, Orlando FL, December 1995.
102. Endobronchial brachytherapy: LDR vs HDR? 18th Annual Mid-Winter Meeting of the American Brachytherapy Society, Scottsdale AZ, December 1995.
103. Clinical trials in Neuro-Oncology I: An Introduction. University of Wisconsin, Neurosurgery Grand Rounds, Madison WI, February 1996.
104. Clinical trials of amifostine and radiation therapy. Tannehill SP, Mehta MP. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1996.
105. The physical, biological and clinical basis for radiosurgery. University of Wisconsin, Neurosurgery Grand Rounds, Madison WI, March 1996.

106. Clinical trials in Neuro-Oncology II: A review of current trials. University of Wisconsin, Neurosurgery Grand Rounds, Madison WI, March 1996.
107. The current and future management of metastatic tumors: The role of fractionated radiation therapy with or without radiosurgery. The Joint Section on Stereotactic and Functional Neurosurgery and the 46th Annual Meeting of the Congress of Neurological Surgeons, Montreal Canada, September 1996.
108. Stereotactic radiation: Indications for metastatic tumors. 38th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Los Angeles CA, October 1996.
109. Refresher Course: High dose rate brachytherapy for endobronchial and endoesophageal tumors. 38th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Los Angeles CA, October 1996.
110. The evolving role of chemotherapy in adult brain tumors: Innovative cancer therapy for tomorrow. Chemotherapy Foundation Symposium XIV, Mount Sinai School of Medicine, New York NY, November 1996.
111. Radiation therapy and radiosurgery for brain metastases. LINAC Radiosurgery 1996, University of Florida Orlando, FL, December 1996.
112. Economics of radiosurgery. LINAC Radiosurgery 1996, University of Florida, Orlando FL, December 1996.
113. Innovative management strategies for malignant glioma. Loyola University Radiation Oncology Grand Rounds, Chicago IL, January 1997.
114. An ECOG Phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer. Tannehill SP, Mehta MP. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1997.
115. Outcomes research and analysis in radiotherapy. University of Wisconsin Human Oncology Retreat. Madison WI, March 1997.
116. Amifostine and Radiation therapy: Past, Present and Future. Amifostine Advisory Board Scientific Session, Atlanta GA, April 1997.
117. Impact of WWW-aided tools on Neoplastic Diseases Course learning. University of Wisconsin Medical Education Day, Madison WI, April 1997.
118. New radiotherapeutic developments for lung cancer. University of Wisconsin Thoracic Surgery Grand Rounds, Madison WI, April 1997.
119. Malignant tumors-Radiosurgery for metastases. Scientific Session, 3rd Congress of the International Stereotactic Radiosurgery Society, Madrid Spain, June 1997.
120. Brain Metastases: Current Status and role of Radiosurgery. University of Wisconsin Cancer Center Grand Rounds, Madison WI, July, 1997.

121. RTOG Clinical trials for adults with primary malignant brain tumors. Sharing Hope: American Brain Tumor Foundation Symposium, Chicago IL, July 1997.
122. Radiation Pneumonitis: Clinical spectrum, molecular pathophysiology, treatment and prevention. University of Wisconsin Human Oncology Retreat. Madison WI, August 1997.
123. ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for non-small cell lung cancer (NSCLC): Early results and RT quality assurance (QA). 8th World Conference on Lung Cancer Dublin Ireland, August, 1997.
124. Combined modality therapeutic approaches for malignant CNS neoplasms. University of Wisconsin Neurosurgery Grand Rounds, Madison WI, September 1997.
125. Radiation Pneumonitis: An evolving understanding of the clinical syndrome, molecular genesis, factors influencing incidence and possible protection. Fifth International Conference on Dose, Time and Fractionation in Radiation Oncology, Madison WI, September 1997.
126. What is the clinical role of WR-2721? Spokane-area CME Symposium. Couer d'Allen, WA, October 1997.
127. Protection of normal tissue from the cytotoxic effects of radiation therapy: role of amifostine. Symposium on Advances in Therapy: Protecting Against the Toxicities of Radiotherapy, Orlando FL, October 1997.
128. Refresher Course: High dose rate brachytherapy for endobronchial and endoesophageal tumors. 39th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Orlando FL, October 1997.
129. Experience with the functional assessment of cancer therapy-lung (FACT-L) in ECOG 4593, a Phase II hyperfractionated accelerated radiation therapy (HART) trial. 39th Annual Meeting of American Society for Therapeutic Radiology and Oncology, Orlando FL, October 1997.
130. A randomized assessment of the value of web-based education for teaching second year medical students. 31st Annual Meeting of the American Association for Cancer Education, Atlanta GA, October 1997.
131. Clinical and economic advances in cytoprotection: role on amifostine. 1997 Annual Meeting of the American College of Clinical Pharmacy, Phoenix AZ, November 1997.
132. Advances in the treatment of lung cancer. Lung Cancer Awareness Day, University of Wisconsin, Madison WI, November 1997.
133. Stereotactic Imaging. LINAC Radiosurgery 1997, University of FL, Orlando FL, December 1997.
134. Gliomas - Does Radiosurgery Help? LINAC Radiosurgery 1997, University of FL, Orlando FL, December 1997.
135. Advances in the Management of Inoperable Lung Cancer, ASTRO Satellite Symposium, 1998.

136. Cytotoxic protection by Amifostine against the toxicities of combined chemo-radiotherapy. National Seminar on Amifostine, Puerto Rico, January, 1998.
137. Update in advances in the management of non small cell lung cancer. Scientific Symposium, Radiation Therapy Oncology Group Meeting, Houston TX, February 1998.
138. State of the Art Treatment Options for State III NSCLC: Radiation Therapy Advances; a UW-CME video conference sponsored by Bristol Myers Squibb, Madison WI, March 1998.
139. Ethylol as a radioprotector; the American experience. French seminar on Ethylol, Paris France, March 1998.
140. Web-based multimedia modules for Oncology Grand Rounds. University of Wisconsin Medical Education Day, April 1998.
141. There is no role for CNS brachytherapy. 21<sup>st</sup> Annual Meeting of the American Brachytherapy Society, Albuquerque, NM, June 1998.
142. Primary brain tumors: Role of radiosurgery. 17<sup>th</sup> Annual UICC Meeting, Rio de Janeiro Brazil, August 1998.
143. Current strategies for improving the therapeutic index of radiation therapy: Radiotherapy in lung cancer. 40<sup>th</sup> Annual Meeting of ASTRO symposium, Phoenix AZ, October 1998.
144. Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions. 40<sup>th</sup> Annual Meeting of ASTRO, Phoenix AZ, October 1998.
145. Management of brain metastases. 40<sup>th</sup> Annual Meeting of ASTRO, Phoenix AZ, October 1998.
146. Gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer for primary and metastatic brain tumors. Society for Neuro-Oncology 3<sup>rd</sup> Annual Scientific Meeting, San Francisco CA, November 1998.
147. The role of whole brain radiotherapy: Is it necessary? LINAC Radiosurgery 1998, Orlando FL, December 1998.
148. Is radiosurgery cost effective? LINAC Radiosurgery 1998, Orlando FL, December 1998.
149. Review of clinical experience with amifostine. ALZA Multidisciplinary Oncology Board Meeting, Atlanta GA, January 1999.
150. Malignant lesions: Role of radiation therapy and radiosurgery in brain metastases. ISRS Annual Meeting, Sydney Australia, February 1999.
151. Glial tumors: Role of radiosurgery. ISRS Annual Meeting, Sydney Australia, February 1999.
152. Sanghavi S, Mehta M: Amifostine as a radioprotector. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1999.



153. Kesslering C, Mehta M: Gadolinium texaphyrin, a novel radiosensitizer. Wisconsin Society of Radiation Oncology, Oconomowoc WI, February 1999.
154. What have we learned about lung cancer from randomized trials over the last two decades? Dubuque IA, March 1999.
155. Preliminary results from the run-in phase of randomized Phase III trial of Gd-Tex in the management of brain metastases. San Francisco CA, April 1999.
156. Management of brain metastases: does aggressive therapy improve the outcome? Gadolinium-Texaphyrin Clinical Investigator Meeting. San Francisco CA, April 1999.
157. Pediatric Brain Tumors: Innovative therapeutic approaches-radiotherapy. 4<sup>th</sup> International Symposium on Special Aspects of Radiotherapy, Berlin Germany, April 1999.
158. Tomotherapy: Where are we going? Radiation Oncology and Medical Physics Visiting Professor Lecture Series, Stony Brook University Hospital, Stony Brook NY, May 1999 (Visiting Professor)
159. Does radiosurgery have a place in the management of malignant glioma? Radiation Oncology and Medical Physics Visiting Professor Lecture Series, Stony Brook University Hospital, Stony Brook NY, May 1999 (Visiting Professor).
160. Current status of radiosensitizers for pediatric CNS tumors, CCG, Denver CO, May 1999.
161. Incorporating high dose rate brachytherapy in the management of lung cancer. The Regional Cancer Center, Erie PA, July 1999.
162. Current role of radiation therapy in lung cancer. The Regional Cancer Center, Erie PA, July 1999.
163. Current recommendations in the management of brain metastases. CNI Khadiwala Memorial Lecture, Denver CO, September 1999.
164. Advances in radiation oncology for brain tumors. CNI Khadiwala Memorial Lecture, Denver, CO, September 1999.
165. Use of Amifostine with Radiation Therapy. Cleveland Clinic Cancer Center Dinner Meeting, Cleveland, OH, September 1999.
166. Introduction to advances in the management of non-small cell lung cancer. ASTRO/ACR Fall Conference, , Washington, DC. September 1999.
167. Overview of Radioprotection with Specific Emphasis on Amifostine. Rush Presbyterian Hospital, Chicago, IL, October 1999.
168. Use of Amifostine in Radiotherapy and Combination Chemoradiotherapy. Northern Illinois Cancer Center. Chicago, IL, October, 1999.
169. Radioprotection with Amifostine. Alza Pharmaceuticals Dinner Meeting, Chicago, IL, October 1999.

170. Use of Amifostine in Clinical Radiation Oncology. Southern California Radiation Oncology Society, Los Angeles, CA, October 1999.
171. Results of the lead-in phase of the randomized trial of Motexfin-Gadolinium in brain metastases. ASTRO Satellite Symposium: Pharmacocyclics Investigators Meeting, San Antonio TX, November 1999.
172. Radiation Oncology–Sensitizers and New Modalities of Therapy. State of the Art Therapy for Children with Brain Tumors. Pediatric Neuro-Oncology Symposium, University of Minnesota, Minneapolis MN, November 1999.
173. Outcomes, measures and cost-effectiveness for radiosurgery. LINAC Radiosurgery 1999, Orlando FL, December 1999.
174. Evolving technologies: Tomotherapy. LINAC Radiosurgery 1999, Orlando FL, December 1999.
175. Review of management approaches for brain metastases. Schering-Plough Temozolomide Brain Metastases Advisory Board. Keystone, CO. February 2000.
176. A multi-center database analysis predicting survival benefit for brain metastases patients treated with radiosurgery. 82<sup>nd</sup> Annual Meeting of the ARS, London, England, April 2000.
177. Radiation Pneumonitis: The syndrome, pathogenesis, and prevention. University of Wisconsin, Division of Pulmonary Medicine Grand Rounds, April 2000.
178. The Role of Radiotherapy and Evolving Advances for the Management of Primary CNS Tumors. American Association of Neurology, Annual Meeting, San Diego, CA, April 2000.
179. The Future of Imaging and Radiation Sciences. Joint Centers for Radiation Therapy, Harvard Medical School, Boston, MA, May 2000, (Visiting Professor).
180. The Current Status of Combination Chemoradiotherapy in Non Small Cell Lung Cancer. 36<sup>th</sup> Annual ASCO meeting, New Orleans, LA, May 2000.
181. High Dose Rate Brachytherapy for Endobronchial Lung Lesions. University of Iowa Radiation Oncology Symposium, Iowa City, IA, June 2000, (Visiting Professor).
182. Tomotherapy. University of Iowa Radiation Oncology Symposium, Iowa City, IA, June 2000 (Visiting Professor).
183. The Impact of Tomotherapy on CNS Tumors. RTOG Semi-Annual Meeting, Montreal Canada, June 2000.
184. Radioprotection with Ethylol. Medical Education Resources/ALZA Pharmaceuticals “Treating and Protecting Your Cancer Patients” Symposium, Salt Lake City, UT, July 2000.
185. Combined Modality Treatment of Locally Advanced Non-Small Cell Lung Cancer. Gundersen Lutheran Clinic Medical Education Program, LaCrosse, WI, July 2000.

186. The Clinical Implementation of Tomotherapy. University of Wisconsin Comprehensive Cancer Center Grand Rounds Program, Madison, WI, July 2000.
187. Radiotherapy Advances for Pediatric Tumors. University of Wisconsin Children's Hospital, Caring for Children with Brain Tumors Program, Madison, WI, September 2000.
188. Xcytrin™ (Motexafin Gadolinium) and Whole Brain Radiation for Patients with Brain Metastases: Lead-In Phase to Randomized Trial – Final Results., 42nd Annual Meeting of ASTRO, Boston MA, October 2000.
189. Radiotherapy for Brain Metastases. Society for Neuro-Oncology 5th Annual Scientific Meeting, Chicago, IL, November 2000.
190. Whole Brain Radiotherapy: Why is it Standard? LINAC Radiosurgery-2000 Meeting, Orlando, FL, December 2000.
191. Low Grade Glioma: Case Discussions: LINAC Radiosurgery-2000 Meeting, Orlando, FL, December 2000.
192. Metastatic Brain Tumors: Case Discussions: LINAC Radiosurgery-2000 Meeting, Orlando, FL, December 2000.
193. Tomotherapy: McGill University, Oncology Grand Rounds, Montreal, Canada, March 2001 (Visiting Professor).
194. Brain Metastases: Current Issues: McGill University, Oncology Grand Rounds, Montreal, Canada, March 2001 (Visiting Professor).
195. Non Small Cell Lung Cancer: Role of Radiotherapy: Royal Victoria Hospital, McGill University, Oncology Grand Rounds, Montreal, Canada, March 2001 (Visiting Professor).
196. Brain Metastases: Current Issues: Radiation Oncology Conference, Hospital Notre Dame, Montreal, Canada, March 2001 (Visiting Professor).
197. Primary Brain Tumors: ASTRO Spring Refresher Course, Chicago, IL, March 2001.
198. Phase I trial of Motexafin-Gadolinium and radiotherapy for intrinsic pontine glioma. NCI/CTEP Drug Development Phase I meeting, NCI, Bethesda, MD, March 2001.
199. The Future of Imaging and Radiation Sciences: Colorado Cancer Research Institute, Denver, CO, March, 2001.
200. Tomotherapy: Radiation Oncology Grand Rounds, University of Pennsylvania, Philadelphia, PA, April, 2001. (Visiting Professor).
201. The Future of Imaging and Radiation Sciences: Cancer Center Grand Rounds, University of Pennsylvania, Philadelphia, PA, April, 2001. (Visiting Professor).
202. Utilizing Tomotherapy to Test New Radiotherapy Processes. Mayo Clinic Tumor Biology Seminar, Rochester, MN, May 2001.

203. Activities of the RTOG Brain Tumor Committee, 1996-2001. 14<sup>th</sup> International Conference on Brain Tumor Research and Therapy, Asheville, NC, May 2001.
204. Recent Activities of the ECOG Brain Tumor Committee. 14<sup>th</sup> International Conference on Brain Tumor Research and Therapy, Asheville, NC, May 2001.
205. Temozolomide for the Treatment of Brain Metastases from Solid Tumors. Schering-Plough Advisory Board Meeting, Chicago, IL, June 2001.
206. Brain Metastases: Where Are we Going? University of Wisconsin, Neurology Grand Rounds, Madison, WI, June 2001.
207. Current Clinical Research Opportunities for CNS Tumors. RTOG New Investigators Meeting, Philadelphia, PA, July 2001.
208. Role of Radiotherapy in Brain Tumors. American Brain Tumor Association, Chicago, IL, July 2001: Results of trials with an oral chemotherapy agent for the treatment of brain metastases: Breakthroughs in the Treatment of Brain Metastases: Oral Chemotherapy. A CME Web Conference, September 2001.
209. Lung Cancer: Dose Escalation Matters. Sixth International Conference on Time Dose and Fractionation, Madison, WI, September, 2001.
210. Clinical Implementation of Tomotherapy. WISRO/AAPM Conference on IMRT, Milwaukee, WI, October 2001.
211. Clinical Research Opportunities with Tomotherapy. 50<sup>th</sup> Anniversary for the first Use of the Cobalt 60 Radiotherapy Symposium, London, Ontario, Canada, October 2001.
212. Biologically and Physically Targeted Treatment for Lung Cancer. Scientific Panel. 43<sup>rd</sup> Annual Meeting of the American Society for Therapeutic Radiation Oncology, San Francisco, CA, November 2001.
213. Impairment of neurocognitive function in brain metastases patients: baseline results from the Phase III trial with Motexafin Gadolinium. American Society of Therapeutic Radiation Oncology, San Francisco, CA, November 2001.
214. ECOG Clinical Trials: Potential Role for Ethylol. MedImmune Medical Advisory Board Presentation, Sonoma, CA, November 2001.
215. Clinical Trials with Motexafin Gadolinium. Redox Modulation: A Novel Approach to Potentiate the Effect of Radiation Therapy. ASTRO Satellite Symposium, San Francisco, CA, November 2001.
216. CNS Tumor Clinical Trials Addressing Resistance to Radiation Therapy. Education Day, Society for Neuro-Oncology, Washington DC, November 2001.
217. Impaired Neurocognitive Function in Brain Metastases Patients Is Strongly Correlated With Worse Quality Of Life: Baseline Results From The Phase III trial of Motexafin

- Gadolinium. 1<sup>st</sup> World Federation of Neuro-Oncology/Society for Neuro-Oncology Meeting, Washington D.C., November, 2001.
218. Glioblastoma Multiforme: The Phase II RTOG Experience. 1<sup>st</sup> World Federation of Neuro-Oncology/Society for Neuro-Oncology Meeting, Washington D.C., November, 2001.
219. Alchemy, Detection, Precision Guidance and Radiotherapy. The 15<sup>th</sup> Annual Simon Kramer Lecture, Jefferson Medical College, Philadelphia, PA, December 2001.
220. Radiosurgery for benign disorders: results. treatment planning and complications. Neurosurgical Grand Rounds, University of Wisconsin, Madison, WI, February 2002.
221. Integrated CT/Linear Accelerator. Finding the Cures- Part II, 4<sup>th</sup> Annual Cleveland Clinic Neuro-Oncology Symposium, Naples, FL, February 2002.
222. Brain Metastases: Current Treatment: Temozolomide Investigators' Meeting, Carlsbad, CA, February 2002.
223. Brain Metastases: Future Directions with Temozolomide: Temozolomide Investigators' Meeting, Carlsbad, CA, February 2002.
224. Use of Temozolomide in Brain Metastases and Lung Cancer: Panel. Temozolomide Investigators' Meeting, Carlsbad, CA, February 2002.
225. Future Directions in Radiation Oncology: The Integration of Biology, Technology and Medicine, MD Anderson Cancer Center, Houston, TX, March 2002 (Visiting Professor).
226. Current Role of Radiation Therapy in Locally Advanced Lung Cancer, MD Anderson Cancer Center, Houston, TX, March 2002 (Visiting Professor).
227. Radiation Oncology in the New Millenium. Wayne State University, Detroit, MI, March 2002 (Visiting Professor).
228. Locally Advanced Non Small Cell Lung Cancer. Wayne State University, Detroit, MI, March 2002 (Visiting Professor).
229. Evolving role of Temozolomide: Brain Metastases, Glioma and Lung Cancer. Schering-Plough Temozolomide Training Conference, San Diego, CA, March 2002.
230. Low Grade Gliomas: Role of Radiotherapy. Neurosurgical Grand Rounds, University of Wisconsin, Madison, WI, March 2002.
231. Evolution in Medulloblastoma Treatment. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.
232. Non Small Cell Lung Cancer: Dose Escalation Matters. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.
233. Radiosurgery for Brain Metastases. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.

- 234. New Approaches in the Treatment of Malignant Glioma. Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 2002.
- 235. Tomotherapy. North Central Chapter of the American Association of Physicists in Medicine, Spring Semi-Annual Meeting, Wausau, WI, May 2002.
- 236. What is Tomotherapy? Wisconsin Oncology Network, Annual Meeting, Madison, WI, May 2002.
- 237. Evaluation and Management of Brain Metastases. 38<sup>th</sup> Annual ASCO meeting, New Orleans, LA, May 2002.
- 238. Results from the Phase III Trial of Motexafin Gadolinium (MGd) in Brain Metastases. 38<sup>th</sup> Annual ASCO meeting, New Orleans, LA, May 2002.
- 239. Glioma: Unmet Clinical Needs. Pretarget Radioimmunotherapy Scientific Advisory Board, Washington DC, July 2002.